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INTRODUCTION 
  
                                                                           
ABSTRACT 
 
BACKGROUND AND OBJECTIVES 
 The cancer of breast with its uncertain cause has captured the 
attention of physicians throughout the ages. It is one of the most common 
carcinoma occurring in females and it is a devastating illness both physically 
and mentally. In India, Breast cancer is second most common, malignancy 
among women next to Ca cervix.According to the National Cancer Registry, 
Bangalore has the highest age adjusted incidence rate in India (36.6). 
Chennai ranks third (32.6). 
GLOBOCAN (WHO) reports that India has the highest number of 
breast cancer deaths in the world (70218) followed by China (47984) and 
USA(43909) 
 
AIM OF THE STUDY  
The purpose of the study is to identify the prognostic factors in 
primary carcinoma breast and  emphasize the need of awareness and public 
education regarding carcinoma breast and its early detection 
The utility of prognostic factors lies not only in their ability to 
prognosticate the outcome of the disease but also in detecting early disease, 
monitoring of disease course, screening for recurrent diseas 
                                                                           
METHODOLOGY 
 
STUDY DESIGN AND SAMPLING: 
This is a prospective analytical study of 95 Cases of Cancer Breast diagnosed and 
treated at KAPV Government Medical College and Mahatma Gandhi Memorial 
Government Hospital, Tiruchirapalli over a period of 2 years from May 2012 to August 
2014. 
                    
 At presentation a detailed history was taken and clinical examination done. 
Diagnosis was confirmed histologically and investigations like Blood Biochemistry, chest 
X-ray, ultrasound abdomen were also done to stage the disease. In patients presenting 
with locally advanced breast disease or metastatic disease investigations like CT 
abdomen, CT chest, mammogram of opposite breast, pleural fluid and ascitic fluid 
cytology were done. 
 
 The modality of treatment was decided based on stage of disease at 
presentation and operability. Most of the patients with early breast cancer I 
II A, II B, III A underwent modified radical mastectomy.  
 
 Inoperable stage IIIA,IIIB,IIIC were treated with neoadjuvant 
chemotherapy followed by Modified radical mastectomy. Patients with 
Metastatic disease received palliative chemotherapy and radiotherapy. 
                                                                           
 
 All cases were followed up at monthly interval with clinical 
examination, blood count and biochemistry, ultrasound abdomen, chest X 
ray, Mammography was done at 3 monthly interval during the follow up 
period. Data obtained were recorded in a specific proforma and analysed in 
systematic way. 
INCLUSION CRITERIA 
  All histologically proven cases of cancer breast were included in the 
study. Immunohistochemical studies of ER, PR receptors were  done in 20 
patients 
 
EXCLUSION CRITERIA 
 patients who where operated and referred for further management from 
outside hospital were excluded from the study. 
 
RESULTS  
1. The commonest age of presentation was 40 – 50 years of age. 
2. About 47.36 were premenopausal and 46.31 were postmenopausal 
5.26% were Nullipara 
3. Commonest mode of presentation was painless lump in 46.31%. 
                                                                           
4. Most of the patients presented with stage III  disease 62.09%. 
5. Lymphnode positivity during presentation was about 69.46%. 
6. Invasive ductal carcinoma was the commonest pathological variety in 
our stage. Histological grade I was found in 56.84%. 
7. Most of our patients presented with tumor size more than 5 cm 
(67.36%).  
8. Modified Radical mastectomy was done in 90 patients. Toilet 
mastectomy  was done in 5 patients presenting with 
ulceration/fungating lesions  
9. Resected margins were found to be positive in 5 patients all of them 
were given radiotherapy. Three of them developed locoregional 
recurrence 2 developed metastasis. One in lung, one in brain.  
10. Lymphnode examination for metastatic deposits in pathological 
specimen showed positivity in 49 patients. More than 6 nodes were 
positive for metastatic deposits in 13 patients. Of which 4 developed 
locoregional recurrence and one developed liver, lung metastasis. One 
patient with supraclavicular node developed spine metastasis.  All 
patients were treated with chemotherapy and radiotherapy.  
                                                                           
11. Histologic grade 1 found in 44.21 of patients, grade 3 found in 
10.52% of our patients (10 Pts) of which 3 had locoregional 
recurrence.  2 developed lung secondaries during the follow up period.  
12. Patients who developed lung metastasis had Tumor size more than 
8cm during presentation and 1 of them had histological grade III 
invasive ductal carcinoma. Supraclavicular node was involved in one 
patient.  
13. One patient with brain metastasis had Tumor size of 6 cm during 
presentation, she had more than 6 nodes positive for deposits in 
pathological resection specimen.   
14. .One patient who developed both spine and liver metastasis presented 
with tumor involving all quadrants.  
15. In the hormone receptor study done in 20  cases .(10 cases in 
premenopausal age group and 10 cases in postmenopausal age group), 
estrogenreceptor positivity was seen in 65%  (13cases), negativity for 
both receptors in 35% (7 cases ) with increase in positivity in older 
age group(50-59 years).  
 1. ER+, PR- tumours (5/10 cases) are more prevalent in 
postmenopausal age group constituting 50%. 
                                                                           
 2. Special histological variants like papillary carcinoma, lobular 
carcinoma are positive for ER and PR.Medullary and Metaplastic 
variants are negative for both receptors. In our study, ER /PR negative 
found in 7 patients.  Among them  one patient with ER/PR –ve 
medullary carcinoma developed local recurrence, and one patient with 
ER/PR –ve metaplasic carcinoma developed lung metstasis. 
 
16. Nottingham Prognostic index was found to have direct correlation 
with prognosis in our study. In 32 of our patients with NPI more than 
5.4, 5 had local  recurrence, 3 had lung metastasis, 2 developed spine 
metastasis and one developed brain metastasis during follow up.     
 
 
 
CONCLUSION 
  The prognostic markers   in carcinoma breast which needs to be 
routinely assessed are axillary lymphnode status, tumour size, histologic 
grade, estrogen  and progesterone receptor status, post operative findings 
like positive margins as they are needed  in planning  of adjuvant treatment. 
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INTRODUCTION 
 
Carcinoma breast is the world’s most common cancer among 
females.  
It is one of the most common carcinoma occurring in females and it 
is a devastating illness both physically and mentally. 
 In India, it is the leading cancer among women in cities and 
second most common cancer in rural women. According to the National 
Cancer Registry, Bangalore has the highest age adjusted incidence rate in 
India (36.6). Chennai ranks third (32.6). 
GLOBOCAN (WHO) reports that India has the highest number of 
breast cancer deaths in the world (70218) followed by China (47984) and 
USA(43909) 
 
  
                                                                           
 
 
 
 
 
 
 
AIM AND 
OBJECTIVE   
                                                                           
 
 
AIM OF THE STUDY 
The purpose of the study is to identify the prognostic factors in 
primary carcinoma breast and  emphasize the need of awareness and 
public education regarding carcinoma breast and its early detection.  
The utility of prognostic factors lies not only in their ability to 
prognosticate the outcome  of the disease but also in detecting early 
disease, monitoring of disease course, screening for recurrent disease 
 
OBJECTIVES OF THE STUDY 
1. To study the incidence of carcinoma breast in relation with age and 
socioeconomic status of patients. 
2. To study the relationship of carcinoma breast with menstrual status 
and  menstrual history. 
 
3. To study the relationship of carcinoma breast and use of hormonal 
pills. 
 
4. To study the TNM stage at which the patients report to hospital and 
its relation to prognosis. 
 
5. Relationship of Tumor size to prognosis 
 
                                                                           
 
 
6. To study the relationship between the number of lymph nodes in 
the axilla in relation to prognosis. 
 
7. Significance of histologic tumour type in relation to prognosis. 
 
8. Relationship of histologic grade of tumour and prognosis.  
9. Relationship of positive resection margins and prognosis.  
10. Evaluation of  hormone receptor status  namely estrogen and 
progesterone receptor  (ER, PR) in carcinoma breast, distribution 
of  ER,PR receptors in different age groups,pre  and post 
menopausal   women and to identify the hormone receptor status in 
different histological types of  breast carcinoma. 
11. .To suggest the prognostic factors that can be assessed and 
routinely followed up in    carcinoma breast 
  
                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
  
                                                                           
 
 
REVIEW OF LITERATURE 
AGE 
A few decades ago, 65 to 70 percent of breast cancer patients were 
women above 50 years. Women under 50, constituted only 30 to 35 
percent.  
However, in recent studies, by NCRP, breast cancer in women 
under 50 years  of age has risen to 49 percent. 
 
SEX 
 Male breast cancer constitute less than 1% of the total incidence 
with female to male ratio 1 : 0.01. 
 
SOCIO ECONOMIC STATUS 
 According to world statistics, cancer breast was more common in 
women with higher socio economic status. 
 
DIETARY FACTORS 
 Weight correlate with risk for carcinoma breast. However, studies 
have not demonstrated a causal relationship between high fat or 
cholestoral rich diet and carcinoma breast.  Other dietary factors include 
Vitamins A, C, E and selenium which are thought to prevent cancer 
through antioxidant properties. Vitamin D decreases cell proliferation and 
                                                                           
 
 
facilitates cell differentiation and its deficiency has been postulated to 
cause breast cancer. 
 
There is increasing evidence that alcohol intake increases a person’s 
chance of developing breast cancer. Relative risk for one unit of alcohol 
per day is 1.1 and increases to 1.3 to 1.5 if intake increases to two glasses 
a day. 
 
SMOKING 
Cigarette smoke produces mutations which have  been demonstrated in  
breast fluid indicative of a direct carcinogenic effect. However, women 
smokers have a lower BMI, low levels of urine estrogen and early 
menopause,  indirectly making them less susceptible to postmenopausal 
breast cancer.  
 
IONIZING RADIATION  
 Women treated with radiotherapy for Hodgkins lymphoma and 
post partum mastitis are more prone to develop carcinoma breast. Women 
treated with irradiation under the age of 35 show an obvious increase in 
risk of developing carcinoma breast,and latent time  of 10 to 15 years. 
Chest wall exposed to high amount of ionizing radiation increase risk of 
to develop carcinoma breast.  
 
                                                                           
 
 
EXERCISE 
Physical activity and exercise decrease the risk of cancer. This 
slight protective effect is more effective in premenopausal women, 
women with normal BMI and those who have had full term pregnancies.  
 
ENVIRONMENTAL TOXINS 
Environmental toxins like organochlorine pesticides are thought to 
have estrogenic effects on the human body. However, there are 
insufficient studies to come to a conclusion. 
 
 
HORMONAL INFLUENCES: 
  Early menarchy, high frequency of ovulation, and high levels of 
urinary estrogens are associated with higher risk of carcinoma breast.  
Cancer cells secrete growth promoters ( EGF, TGF, PDGF, FGF)  and 
growth inhibitors (TGF – B).  Studies show that estrogen induced 
secretion of autocrine factors and their interaction with hormone 
receptors expressed by tumour cells  play a role in tumor progression. 
Breast feeding,  early age of first full term pregnancy, late menarche and  
early menopause are protective because of less estrogen exposure. 
  
                                                                           
 
 
MENSTRUAL STATUS 
  For every year of delay in menarche, there is an apparent reduced 
risk of carcinoma breast  by 20%. Women experiencing menopause after 
55 years have twice  risk of developing breast carcinoma compared to 
women attaining natural menopause before 45 years 
 
PARITY 
 The relative risk of developing breast carcinoma breast  in 
nulliparous women is 1.4.In  anovulatory cycles there is more chance of 
developing carcinoma breast due to increased exposure to endogenous 
estrogen in the absence of progesterone.  
 
AGE AT FIRST PREGNANCY 
Women having first full term pregnancy before 25 years have 36% 
lesser incidence of carcinoma breast compared to nulligravida. This 
advantage is not afforded by women having late age of first parity. The 
terminal differentiaton of breast cells occurring in the first full term 
pregnancy reduce the likelihood of malignant transformation.  
 
LACTATION 
 A reduction in risk of cancer have been documented but no such 
effect was detected in postmenopausal females. 
                                                                           
 
 
OOPHERECTOMY  
Oopherectomy below 40 years is protective. 
ORAL CONTRACEPTIVES AND CANCER RISK Birth control 
pills recent users has slightly higher chance of  to develop breast 
cancer.After stoppage of  oc’s 10 years OR more return to  normal risk 
level those with oc’s  never used before. 
 
HORMONE REPLACEMENT THERAPY AND CANCER RISK  
The impact of HRT use on breast cancer risk varies depending 
upon BMI, breast density,race and ethinicity. Low or normal BMI with 
HRT use has high chance of developing breast cancer. However, HRT 
use among women with high BMI does not increase the risk. 
 
DES USE AND CARCINOMA BREAST 
           DES use increased the possibility  of developing carcinoma breast  
by 30%. However, this probability of chance return to normal over a 
period of time. 
 
ABORTION AND BREAST CANCER 
Spontaneous  and induced abortions have no impact on risk of 
developing carcinoma breast. 
 
                                                                           
 
 
 PAST HISTORY OF CARCINOMA BREAST   
  For patients younger than 45, the risk for contralateral breast is five 
to six times that of general population. In absolute terms the actual risk 
varies between 1% per year in young patients to 0.2% in older patients. 
 
HISTORY OF BENIGN BREAST DISORDER 
 Patients with history of proliferative disease or atypical ductal or 
lobular hyperplasia have increased risk of developing cancer breast. 
Relative risk of invasive cancer breast based on American college of 
pathologists consensus statement is as follows. 
 
NO INCREASED RISK: 
Fibroadenoma, fibroadenosis, hyperplasia, squamous, 
apocrinemetaplasia, micro, macrocysts, ductal ectasia, periductal mastitis 
has no increased risk of breast cancer 
 
SLIGHTLY INCREASED RISK (1.5 – 2 TIMES)  
Moderate or florid solid or papillary hyperplasia, papilloma with 
fibro vascular core has 1.5 to 2 times increased risk of carcinoma breast 
                                                                           
 
 
MODERATELY INCREASED RISK 
Atypical hyperplasia with positive family history has 20% risk to 
develop carcinoma breast at 15 years.Atypical hyperplasia  of breast  
cumulative risk of breast cancer is 10% at  55 months 
 
FAMILIAL BREAST CANCER:  
Women with BRCA1and BRCA2 mutations have a 40 to 55% risk 
of developing carcinoma breast during life time. Carriers with previous 
history of breast cancer have a 5% per year increasing risk of  developing 
carcinoma in the opposite breast. 
BRCA1 situated in chromosome 17q and BRCA2  is situated in 
chromosome 13q Most of cases of cancer breast in families are due to 
expression of random mutations rather than due to genetic defect So 
prophylactic mastectomy is limited to cases of 
1. Young patients whose first degree relative had bilateral 
premenopausal breast cancer. 
2. Families with an established genetic defect. 
3. Families with many members affected with a consistent 
pedigree. 
  
                                                                           
 
 
Syndromes associated with multiple cancers which can run in families 
include 
 Lynch type II  –  cancer breast and ovary 
 Lifraumeni Syndrome  –  soft tissue sarcomas, brain tumor, 
                        leukaemia, melanoma and cancer  
      breast. 
RISK FACTOR FOR BREAST CANCER 
MAJOR: Gender, Age, Family History, Personal History of contra 
lateral cancer breast, Benign proliferastive changes with atypia, Non 
invasive carcinoma 
 
MINOR: Early menarche, obesity , Late menopause, Low dose radiation 
CONTROVERSIAL RISK FACTORS  
- Alcohol intake, Smoking, OCP / HRT, 
Abortion, Diet 
 
CLINICAL PRESENTATION 
Most women with carcinoma breast will present with one of the 
following.  
1) Painless hard lump with retraction of nipple. 
2)  A lump, which may be recurrent after biopsies for benign disease 
                                                                           
 
 
3) Lump in the contra lateral breast after breast cancer of opposite 
side 
4) An axillary/supraclavicular node mass.  
5) Symptoms due to metastatic disease. 
6) Discharge from nipple-mostly are benign but may be the first sign. 
As disease advances locally there may be skin involvement with 
following features.  
7) Peaud’ orange:- 
Blockage  of cutaneous lymphatics cause lymphatic oedema  
and leads to deepening of mouth of sweat gland  and  giving 
an orange skin appearance. 
8) Frank ulceration of the overlying skin 
9) Fixation to the chest wall. (cancer-en-cuirasse) 
The chest wall skin infiltrated with cancer has been likened 
to a coat    described as cancer ‘en-cuirasse’ generally occurs 
in cases with local recurrences after mastectomy or 
occasionally following irradiation to the chest wall 
  
                                                                           
 
 
PATHOLOGY 
Pathological classification of carcinoma Breast (WHO) 
(I) EPITHELIAL TUMOURS    
 1.    Non-invasive 
- Intraductal ca <DCIS> 
- Lobular carcinoma in situ <LCIS> 
            II   Invasive type 
a)  ductal carcinoma invasive type(not otherwise 
specified) 
b) ductal carcinoma  invasive type(predominant DCIS) 
c) Mucinous  
d) Medullary 
e) Papillary  
f) Lobular 
g) Adenoid cystic 
h) Secretory 
i) Apocrine 
j) Carcinoma with metaplasia 
(i) Squamous 
(ii) Spindle cell 
(iii) Cartilaginous and osseous  
(iv) Mixed 
k) Others 
                                                                           
 
 
LOBULAR 
a) Invasive Lobular carcinoma 
b) Combined Ductal and Lobular. 
c) Paget’s disease of Nipple. 
 
(II) MIXED CONNECTIVE TISSUE AND EPITHELIAL 
TUMOURS 
Fibroadenoma, carcinosarcoma,cystosarcomaphylloides  
 
(III) MISCELLANEOUS TUMOURS 
        Soft tissue tumours, Skin Tumours, Tumours of Hemato poietic, 
lymphoid tissues 
 
(IV) UNCLASSIFIED 
(V) MAMMARY DYSPLASIAS 
(VI) TUMOUR LIKE LESIONS  
- Duct ectasia, Inflammatory pseudotumours, Hamartomas 
Gynaecomastia, Others 
 
 
 
 
 
                                                                           
 
 
 
Table 1:- DISTRIBUTION OF HISTOLOGICAL TYPES OF 
BREAST CANCER 
Invasive carcinoma Percentage(%) 
Invasive carcinoma NOS type  79 
Lobular carcinoma 10 
Tubular/cribriform  carcinoma 6 
Mucinous carcinoma 2 
Medullary carcinoma 2 
Papillary carcinoma 1 
Metaplastic carcinoma <1 
 
  
                                                                           
 
 
 
Figure 1: Ductal carcinoma in situ (DCIS) 
 
 
Figure 2: Lobular carcinoma in situ (LCIS) 
                                                                           
 
 
 
 
Figure 3: IDC/ Lobular carcinoma 
 
 
 
Figure 4: Invasive lobular carcinoma 
                                                                           
 
 
 
 
Figure 5: Medullary carcinoma of the breast 
 
 
Figure 6: Paget’s disease of the nipple 
 
 
                                                                           
 
 
STAGING OF CANCER BREAST 
The American Joint Committee on Cancer (AJCC) provides a 
strategy for grouping patients with respect to prognosis. This system of 
staging is called TNM classification of breast cancer. 
 
Primary tumor (T) 
TX: Primary tumor cannot be assessed  
T0: No evidence of primary tumor  
Tis: Intraductal carcinoma, lobular carcinoma in situ, or Paget disease of 
the nipple with no associated invasion of normal breast tissue  
Tis (DCIS): Ductal carcinoma in situ 
Tis (LCIS): Lobular carcinoma in situ 
Tis (Paget): Paget disease of the nipple with no tumor. [Note: Paget 
disease associated with a tumor is classified according to the size ofthe 
tumor.]  
T1: Tumor not larger than 2.0 cm in greatest dimension  
T1mic: Microinvasion not larger than 0.1 cm in greatest dimension  
T1a: Tumor larger than 0.1 cm but not larger than 0.5 cm in greatest 
dimension  
T1b: Tumor larger than 0.5 cm but not larger than 1.0 cm in greatest 
dimension  
                                                                           
 
 
T1c: Tumor larger than 1.0 cm but not larger than 2.0 cm in greatest 
dimension  
T2: Tumor larger than 2.0 cm but not larger than 5.0 cm in greatest 
dimension  
T3: Tumor larger than 5.0 cm in greatest dimension  
T4: Tumor of any size with direct extension to (a)  chest wall or (b) skin, 
only as described below  
T4a: Extension to chest wall, not including pectoralis muscle  
T4b: Edema (including peau d’orange) or ulceration of the skin of the 
breast, or satellite skin nodules confined to the same breast  
T4c: Both T4a and T4b  
T4d: Inflammatory carcinoma Regional lymph nodes (N) 
NX: Regional lymph nodes cannot be assessed (e.g., previously removed)  
N0: No regional lymph node metastasis  
N1: Metastasis to movable ipsilateral axillary lymph node(s)  
N2: Metastasis to ipsilateral axillary lymph node(s) fixed or matted, or in 
clinically apparent* ipsilateral internal mammary nodes in the absence of 
clinically evident lymph node metastasis  
N2a: Metastasis in ipsilateral axillary lymph nodes fixed to one another 
(matted) or to other structures  
                                                                           
 
 
N2b: Metastasis only in clinically apparent iipsilateral internal mammary 
nodes and in the absenceof clinically evident axillary lymph node 
metastasis  
N3: Metastasis in ipsilateral infraclavicular lymphnode(s) with or without 
axillary lymph node involvement, or in clinically apparent  
ipsilateralinternal mammary lymph node(s) and in the presenceof 
clinically evident axillary lymph node metastasis; or, metastasis in 
ipsilateral supraclavicular lymph node(s) with or without axillary or 
internal mammary lymph node involvement  
N3a: Metastasis in ipsilateral infraclavicular lymph node(s)  
N3b: Metastasis in ipsilateral internal mammary lymph node(s) and 
axillary lymph  node(s)  
N3c: Metastasis in ipsilateral supraclavicular lymph node(s)  
 
PATHOLOGIC CLASSIFICATION (PN) 
 Pnx - regional nodes cannot be assessed 
 Pno - no regional lymph node metastasis 
 Pn1 - metastasis to mobile ipsilateral axillary nodes  
 Pn1a - only micro metastasis (none > 0.2 cm) 
 Pn1b - metastasis to node > .2 cm 
 Pn1bi - metastasis to 1 – 3 lymph nodes (0.2 – 2 cm) 
 Pn1bii- metastasis to 4 or more nodes (0.2 – 2 cm)  
                                                                           
 
 
 Pn1biii- extension of tumour beyond the capsule of a lymph  
   node metastasis less than 2 cm in greatest dimension 
 Pn1biv- metastasis to node > 2cm 
 Pn2 - metastasis to ipsilateral axillary nodes fixed to each  
   other 
 Pn3 - metastasis to ipsilateral internal mammary nodes.   
  
                                                                           
 
 
Distant metastasis (M)  
MX: Presence of distant metastasis cannot be assessed  
M0: No distant metastasis  
M1: Distant metastasis  
Table 2:- AJCC staging of breast cancer 
Stage Grouping 
0 T1s No Mo 
1 T1 No Mo 
IIA 
T0 
T1 
T2 
N1 
N1 
N0 
Mo 
Mo 
Mo 
IIB 
T2 
T3 
N1 
N0 
Mo 
Mo 
IIIA 
To 
T1 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
Mo 
Mo 
Mo 
Mo 
Mo 
IIIB 
 
 
 
 
T4 
T4 
 
T4 
N0 
N1 
 
N2 
Mo 
Mo 
 
M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
 
  
                                                                           
 
 
MANCHESTER CLASSIFICATION  
Stage I - Tumour confined to breast, skin involvement less than size  
   of tumour 
Stage II - Tumour confined to breast, with mobile palpable axillary  
   nodes 
Stage III - Tumour extends beyond breast tissue, skin involvement  
   more than size of tumour, fixed to underlying fascia, pectoral  
   muscle  
Stage IV - Growth fixed to chest wall, satellite nodules, fixed axillary  
   nodes, supraclavicular nodes, distant metastasis 
 
SPREAD OF BREAST CANCER 
Carcinoma breast spread by following means 
1. Local spread within the breast 
 By  - direct infiltration along ducts 
  - direct infiltration into breast parenchyma 
  - Breast lymphatics  
 Invades skin, pectoral muscles, chest wall 
2. Regional spread 
 Occurs to axillary and internal mammary nodes. 
 Involvement of lymphnodes is an independent prognostic indicator 
 No histological positive nodes - 80% 5 year survival 
 1-3 histological positive nodes - 50% 5 year survival 
 >4 histological positive nodes - 21% 5 year survival 
                                                                           
 
 
LEVEL OF INVOLVEMENT 
Level I - Lymphnodes lateral to border of pectoralis minor 65% 5  
   year survival rate 
Level II - Lymphnodes deep to insertion of pectoralis minor 31% 5  
   year survival  
Level III - Lymphnodes medial to pectoralis minor muscle. 
 
 Lymph passing through either axillary or internal mammary nodes 
reaches the jugulosubclavian venuous confluence. If this is obstructed, 
lymph passes in retrograde way to supraclavicular nodes. 
 Lymph channels also cross the diaphragm where they communicate 
with lymphatics of the liver. 
 
3.Spread by blood stream 
Metastasis occurs to bones, liver, lung, brain, adrenals, ovaries. 
The intercostal veins in addition to draining into azygos, communicate 
with vertebral veins, thus explaining predeliction to axial skeleton. The 
skeletal metastasis are usually osteolytic. Their order of frequency is to 
lumbar vertebra, femur, thoracic vertebra, rib, skull. 
 
                                                                           
 
 
INVESTIGATIONS 
OBJECTIVE  
1. To confirm diagnosis 
2. To know extent of disease 
3. To use the information in predicting response to certain type of 
treatment. 
A. TO CONFIRM THE DIAGNOSIS : FNAC / BIOPSY 
 FNAC - To be done in all palpable, suspicious masses 
- Therapeutic in cysts. 
FNAC PROCEDURE 
The lump is immobilized and if possible the skin over the lesion is 
stretched and cleaned with spirit, so that the needle reaches the target 
easily.  
The instrument is introduced into the lesion, then vacuum is 
created by about 2-3 ml, and the needle is moved back and forth 5-6 
times.By this time in the hub of the needle will shows tissue, if not seen 
then needle is withdrawn from the target till the subcutaneous tissue and 
redirected in other direction to repeat the same procedure.  
Then the syringe is withdrawn filled with air and needle is brought 
in contact with the slide and one drop of tissue is deposited on one, tissue 
is spread with cover slip or a haematological smear is prepared if blood or 
aspirate is more.  
                                                                           
 
 
Following the air dried preparation slide is stained with 
wrights/wrights Giemsa/May Grunnwald Giemsa. If not air-dried it is 
immediately fixed with 95% alcohol and staining is done with H&E 
stain/with pap stain.  
Combination of physical examination, mammography and FNAC 
will produce a diagnostic accuracy approaching 100%. FNAC is done in 
palpable mass, mass on mammogram. Sensitivity of test is approximately 
80%, false negative varies b/w 2-10%. Axillary US – FNAC reliably 
detect the node metastasis arising from both primary invasive ductal and 
lobular tumours.  
 
Advantages: 
Less expensive  
Less invasive  
 
Complications of FNAC: 
Growing out of tumor along needle tract, which is less in case of 
calibre < 20 gauze.  
Acute mastitis  
Pneumothorax  
Haematomas  
 
                                                                           
 
 
Interval of weeks required b/w FNAC and mammography as they 
form hematomas and result in false positive mammographic studies.  
 
Sensitivity of breast FNAC performed on palpable masses is 
reported to be 90 percent. The specificity and predictive value of breast 
FNAC approaches 100 percent because false positive results are rare. 
 
BIOPSY 
 - Core needle biopsy 
 - Open biopsy 
Excisional biopsy  
Incisional biopsy 
 Can be used for histological grading and ER / PR assay  
 
CORE NEEDLE DIRECTED BIOPSY 
Large bore needles are often used  
More invasive  
Better accuracy  
Can perform receptor determinations  
Can be done stereotatically  
USG-guided core biopsy used for preoperative axillary lymph node  
staging 
 
  
                                                                           
 
 
OPEN BIOPSY 
EXCISION  
Removal of all evidence of disease with rim of normal breast 
tissue.  
INCISIONAL  
For larger not amenable to excisional biopsy, incisional biopsy can 
be done. Usually one ml of tumor is required for receptor status study.  
 
NONPALPABLE MAMMOGRAM ABNORMALITY 
1. Needle localized core biopsy under mammographic guidance.  
2. Needle core biopsy directed into lesion under stereo tactic control 
3. USG guided percutaneous biopsy can be done. 
Image directed needle localization done under local anesthesia. 
Wire and hook passed and positioned in area of calcification density 
or suspicious area. Specimen excised with the wire and radiograph 
taken to confirm calcifications  present in biopsy specimen. 
 
IMAGING TECHNIQUES 
MAMMOGRAPHY 
Bilateral mammography is useful as a screening and diagnostic 
tool. In screening mammography, imaging is done in two views.  
 
Medio lateral oblique (MLO)  
                                                                           
 
 
Craniocaudal (CC)  
MLO is the most effective single view because it includes the 
greatest among breast tissue and is the only whole breast view to include 
view to include all of the upper-outer quadrant and axillary tail.  
The medial aspect of the breast is better visualised through CC 
view. It also offers greater detail.  But because of lower specificity of 
single view screening most radiologists believe that screening 
examination should include both MLO and CC views.  
Breast compression is a must in mammography because  
 - Holds breast still.  
 - Brings objects closer to film.  
 - Separates overlapping tissue that might obscure underlying  
   lesions.  
 - Decreases radiation dose of mammography.  
 
Disadvantages of mammography  
- Pain  
- Uncomfortable due to compression of breast  
 
Mammography is done in the following individuals for diagnosis and as a 
part of screening.  
-  Women between 40-49 years-studies should be screened every 12 
to 24 months.  
                                                                           
 
 
- For those>50 years annual mammogram.  
- For women younger than 50 years of age who are in high-risk 
group,   (i, e. those with previous/family h/o breast ca).  
 
DIAGNOSTIC MAMMOGRAPHY 
Also called consultative or problem solving. It is indicated when 
there are clinical findings such as palpable lump or abnormal results on a 
screening examination.  
 
Capabilities 
- Can define the nature of many breast abnormalities.  
- Can identify unexpected malignancy.  
- Can identify multi focal disease.  
 
Indication of Diagnostic mammography;  
- Over 30 years  
- With/without lump before performing biopsy.  
- Detect unexpected lesions of ipsilateral/contralateral breast.  
- Identifying and extensive intraductal component of a palpable 
invasive  
- carcinoma.  
- To detect carcinoma in contra lateral breast after mastectomy.  
                                                                           
 
 
- After surgery before radiotherapy to document all the calcification 
were removed  
- At 6 months interval for 2 years after lumpectomy in later years.  
Normal findings  
Four categories  
1. Breast entirely fat.  
2. Scattered fibro glandular densities.  
3. Breast tissue is heterogenetically dense.  
4. Extremely dense.  
  
Characteristics of malignant breast lesions 
Microcalcification  
Irregular speculation  
Branching calcification  
Clustered calcification 
Architectural distortion 
Loss of symmetry 
 
 
 
 
 
                                                                           
 
 
BENIGN BREAST LESIONS  
CHARACTERISTCS  
Macrocalcification 
Smooth, round lesion 
Radioopaque or radiolucent lesions 
 
MAMMOGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Mammogram showing calcification in benign and 
malignant breast cancer 
                                                                           
 
 
DIGITAL MAMMOGRAPHY  
This type records the radiography image electronically in a digital 
format rather than a film.  
It is left in computer and is displayed on fluorescent monitor 
 
B TO KNOW ANATOMICAL EXTENT OF THE DISEASE 
  1  X RAY CHEST 
 To rule out pulmonary metastasis  
  2.   USG ABDOMEN 
       Used to investigate masses of the breast in young women with dense 
breasts in whom mammogram interpretation is difficult.  
        Distinguish cysts from solid lesion.  
       Used to localise impalpable areas of breast pathology.  
        Although USG is not efficacious as a screening modality, combined  
        mammography and USG pick up more cancers than mammography 
alone.  
        To rule out liver metastasis, free fluid retroperitoneal 
lymphadenopathy 
3. BONE SCAN 
 In stage I and II incidence of skeletal metastasis is 2-6% 
 In stage III it is 14% 
                                                                           
 
 
 Bone scan has a lead of 6-18 months over radiograph in 
demonstrating metastasis. 
 Most bony metastasis appear 20 months to 4 years after 
mastectomy. 
 Bone scan is indicated in higher stage of disease, in patients who 
have bone pains, raised level of serum alkaline phosphatase, positive 
skeletal radiogram, palpable regional or metastatic disease. 
This investigation can identify occult osseous metastases before 
they become radiologically detectable. Bone seeking isotopes such as 
strontium 85 and technetium 99m are generally used.  
(ii) Skeletal survey: 
Usually done in bone scan is positive. All cases of skeletal pain must be 
evaluated.  
4. Liver studies 
Abnormalities in levels of serum enzymes such as alkaline 
phosphatase, lactic dehydrogenase and SGOT are suggestive of liver 
metastasis. An isotope scan of liver using sulphur colloid labelled 
99mTechnitium will give valuable information in doubtful cases, 
supporting clinical and radiological studies. The ultrasound may help in 
detecting the secondary involvement in liver.  
 
 
                                                                           
 
 
 
Figure 8: X-ray lung metastases 
 
Figure 9: X-ray bone metastases 
                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: CT scan showing liver metastasis 
                                                                           
 
 
   
 
Figure 11: MRI scan showing multiple metastases to the brain 
 
5. CAT and MRI 
 They aid in evaluating axilla, mediastinum, supraclavicular area for 
adenopathy. 
  MRI helps to evaluate patients after prosthetic implants. To 
diagnose recurrence after surgery. It is often difficult to predict whether it 
is local recurrence or fibrosis or scarring. In MRI the scar tissue will not 
be enhanced with contrast media whereas the tumour (recurrence) is seen 
as enhanced area. It is a highly effective screening tool in women with 
high risk of breast cancers having positive family history.It is less useful 
than ultrasound in the management axilla both in primary breast disease 
and recurrent disease  
                                                                           
 
 
 
C.ER, PR – AS BASIS FOR RESPONSE TO HORMONAL 
THERAPY: 
As a prognostic factor, ER and/or PR positivity can be correlated 
withdecreased death rate and an improved survival when compared with 
ER, PR negative tumours
52
. It has been documented that 5-year overall 
survival is 83% in ER+/PR+ patients but it is reduced to 69% in the 
receptor negative individuals. 
When patients were treated with tamoxifen for five years, it 
reduced the probability of developing tumour in the opposite breast by 
47%. It was not beneficial to the women with the receptor-negative 
tumours more selective breast cancer treatments. 
          Breast cancer-related deaths havemarkedly decreased with the 
discovery of endocrine agents (e.g. tamoxifen and aromatase inhibitors) 
that selectively target ER- expressing breast tumours. This serves as a 
motivation to continue to define potential druggable targets for hormone 
receptor- and HER2-negative(triple-negative) breast cancers that do not 
respond to endocrine therapies or totrastuzumab and for which cytotoxic 
chemotherapy is the only systemic treatmentoption. In-depth 
characterization of breast tumours is imperative for the development of 
targeted therapies. 
                                                                           
 
 
Hormone receptor status as determined by immunohistochemistry 
correlated with therapy regimens like chemotherapy, hormone therapy. 
 
          All tissues should be analyzed for receptors whenever adequate 
volumes are available more than 60 percent of ER positive tumours will 
respond to adjunctive endocrine therapy 
     Two types of assays are used to quantitate ERS and PRS 
Quantitative analysis of ERS and PRS can be done through two different 
types of assays. 
I. Radiolabelled ligand binding assays are more accurate than 
immunohistochemical assays because of rigorous validation and 
standardization procedures used for the former. An example is the 
Dextran coated charcoal assay. These assays were done on tumor 
cytosols extracted from tumor specimen and hence the unit of such 
assays is femtomoles per receptor protein per milligram of total 
cytosol protein (fmol/mg). The results may range from 3 to 20 
Fmol/mg. These assays require large specimens which should be 
immediately frozen in liquid nitrogen for accurate results. The 
presence of estrogen/tamoxifen in the sampled specimen alters the 
results of this assay. 
 
Immunohistochemical assays and enzyme immunoassays assess ER, 
PR status by monoclonal antibody methods. They have some advantages 
                                                                           
 
 
over radiolabelled ligand assays in not requiring a large specimen sample. 
They can be performed even on archived tissue (formalin fixed and 
paraffin embedded), frozen sections,etc. The presence of estrogen and 
tamoxifen will  not alter the results because these tests quantitate the total 
proteins.  
                  The Immunohistochemistry assay has substituted the older 
methods like ligand binding assay and is nowadays preferred as the mode 
of choice for analysing the hormone receptors. It estimates the proportion 
of cancer cells expressing the positivity.  To a greater extent, there is a 
notification that variations in the procedures and techniques of the assay 
used could make alterations in the results and interpretations. The 
changes can also be due to the study group of patients with distinct and 
modified clinical stages and aggressive phenotypes of carcinomas. 
The outcome will also be influenced by inadequate fixation. So the 
specimens should be obtained immediately after the surgical procedures. 
The commonly used fixatives are formal-saline and neutral buffered 
formalin. The fixation should be quick and the fixative should be evenly 
distributed throughout the specimen 
        A hybrid block which encompasses distinct tissues containing areas 
abundant with receptors admixed with receptor deplete and negative 
tissues should be used. It is likely that the tumour tissues that should be 
evaluated possess normal appreciable breast parenchyma to serve the 
                                                                           
 
 
purpose of positive internal control. The process should be repeated when 
difficulties are encountered in the staining of normal parenchymal tissue. 
The type and grade of the tumour should also be considered so that they 
both have been proved to have impact on the interpretation of inferences. 
This is supported by the fact that the tumours that are well differentiated 
are highly improbable to yield negative results 
 
Scoring system: 
Various respective scoring methods have been imparted in the 
literature. The positivity should be depicted by taking in to account the 
staining in the nuclei of the tumour cell. It is important to estimate the 
entire invasive element of the tumour. The importance of establishing a 
definite scoring system is to make certain that homogeneity should exist 
between various laboratories. On considering this issue retrospectively, it 
is essential to bring emphasis to Allred score assigned by Craig Allred 
few years ago. In 2010, Asim et al added an adjunct for widespread use of 
this method nowadays and supplemented by the study report that the 
sensitivity as well as the specificity of the Allred score was very high in 
contrast to other methods
.
The score is allocated by the estimation of  two 
scores, first is the proportion score from 0 to 1, given by analysing the 
percentage of nuclei in the cells, having taken the stain and secondly, the 
intensity score from 0 to 1 given by exploring the strength and magnitude 
                                                                           
 
 
of staining as negative, weak, average and intense. Both the scores are 
added to give the total score.  
Various rational motives for identifying both the hormone receptor 
positivity and analysing the intensity of the reaction of breast carcinomas 
are as follows: 
1. Several reviewed facts and materials about the evaluation of both 
receptors are accounted to the management of carcinomas with 
metastasis in the view of, greater the percentage and intensity of 
positivity of tumour cells, then higher the possibility of better 
outcome and effects to endocrine therapy. 
 
2. Virtually, there would not be any anticipation of response in 
individuals with breast carcinomas which do not exhibit the 
staining pattern.  
3. The consideration of progesterone receptor  along with estrogen 
receptor is ideal and worth. The tumours that have very low ER 
positivity but high PR positivity could still respond to hormonal 
treatment is the contributory evidence provided by the progesterone 
receptor.  
4. Even though the degree of staining is low in the tumours scoring 2 
or less than 2, the adjuvant endocrine therapy has been proved 
beneficial in those patients too. This highlights and foregrounds 
that it is necessary to develop sensitive and standardised 
                                                                           
 
 
procedures which have the ability to trace out these low receptor 
levels.
 
HER2 / NEU. STATUS 
IHC methods are used to semiquantitively assess HER2/neu status 
through the use of monoclonal antibodies. 
Scoring of HER2 / neu over expression by DAKO Hercep test. 
 Score 3+  -positive - Complete intense staining in more than 
30% of tumour cells 
 Score 2+ -equivocal non uniform or weak  complete 
membrane staining showing circumferential distribution in 
atleast 10% of cells or intense complete staining in less than 
30% cells 
 Score 1- negative- Faintly perceptible membrane staining in 
any proportion of tumour cells or complete membrane 
staining of <10%  
 Score 0- no staining observed 
Gene amplification detected through fluorescence in site 
hybridization (FISH) shows high specificity and is 82% 
concordant with immunohistochemical assays. 
 
 HER2 / neu over expression is associated with poor prognosis 
Studies show that taxanes are highly efficacious in tumors with 
                                                                           
 
 
overexpression of HER2 in relation to HER2 negative tumors. The 
relative risks of recurrence in the two groups are 65% and 35% 
respectively. 
 
MANAGEMENT 
 In the management of carcinoma breast, cure should take 
precedence over cosmesis without disregarding it. Management falls into 
2 main categories. 
- Loco regional control 
- Systemic 
I. SURGICAL MANAGEMENT 
 A century ago William Hallstead published his first report on 
radical mastectomy for control of breast cancer. At that time this was 
considered as appropriate solution to the problem. Later review showed 
that long term rates were not changed despite dramatic reduction in local 
recurrence rate. 
 
 Fisher stated that venous lymphatic communication exist and that 
particles injected into lymphatic drainage of breast rapidly appeared in 
venous circulation. Hence the disease was considered to be systemic long 
before clinical diagnosis was made. Fisher hypothesis indicated that 
variation in local and regional treatment were unlikely to influence  long 
                                                                           
 
 
term cure. A systemic therapy would be necessary from the beginning 
which led to clinical trials of adjuvant systemic therapy 
 Different surgical procedures available are  
 
1) RADICAL MASTECTOMY 
  Here the breast, pectoralis major, regional lymphnodes along 
axilla upto  costoclavicular ligament are resected. 
 
2) EXTENDED RADICAL MASTECTOMY 
  Here the breast, pectoralis major, regional lymphnodes along 
axilla upto  costoclavicular ligament are resected with internal mammary 
nodes are also removed. 
 
3) MODIFIED RADICAL MASTECTOMY 
In modified radical mastectomy, the pectoralis major muscle is left intact 
. 
(i) Patey’s   Modification Pectoralis minor is removed and level  
 I, II, III Lymph nodes are removed. 
(ii) Scalon’s Modification Pectoralis minor divided level I, I, III 
Lymph nodes are removed. 
(iii) Auchincloss Modification Pectoralis Minor is left intact level 
I / II nodes are only removed. 
  
                                                                           
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
Figure 12: Modified radical mastectomy 
                                                                           
 
 
 
Figure 13: Pathological specimen of carcinoma breast 
 
4) BREAST CONSERVING SURGERIES  
i. Wide local excision (lympectomy, tylectomy, segmental or partial 
mastectomy)  
ii. Lump with 1 cm margin of grossly normal breast tissue is removed 
iii. Quadrantectomy 
 
The quadrant of breast containing the lesion is removed. 
  
5) SKIN SPARING MASTECTOMY 
Skin envelope is preserved while removing nipple areola complex, 
all underlying breast & axillary contents followed by immediate 
reconstruction with TRAM Flap or Expandable implants with small graft 
at areola site. 
                                                                           
 
 
 
6) SIMPLE OR TOTAL MASTECTOMY 
Breast, Axillary tail of Spence and lymphnodes along it (low 
anterior group) are removed. This involves the complete removal of all 
mammary gland including the nipple and areola. Elliptical/transverse 
incision is put and surrounding skin is excised depending upon the site 
and size of the tumor or ulceration. Skin flaps are raised to separate from 
the underlying gland and mammary gland is swept off laterally from 
underlying pectoralis major muscle fibers.  
 
AXILLARY DISSECTION 
Axillary lymph node dissection has been part of surgical treatment of  
breast cancer for following reasons.  
 To allow proper staging  
 To provide useful prognostic information  
 To guide for subsequent treatment.  
 To increase potential therapeutic gains  
 
It is recommended for all patients with invasive cancer, as 
pathological staging is most importmant prognostic factor with survival 
rate being related to  
axillary node status. 
  
                                                                           
 
 
Advantages of complete axillary LN dissection are as follows  
 No risk of under staging the disease, when level 1 and 2 are done 
risk of under staging the disease is at least 2.6%.  
 No additional surgical treatment required if the axilla is 
pathologically positive  
 Complete dissection minimizes the risk of local recurrence.  
 It is widely accepted that involvement of axillary nodes occurs in a 
progressive manner from lower to higher level. But when level 1 
node are positive chances  of higher level being positive varies 
from 22-42.9% and node positivity increases with tumor size. . 
 
Axillary lymph node status is the most important prognostic factor 
of  breast cancer.  The number of lymph nodes retrieved in ALND during 
surgery varies considerably. A minimum of 10 nodes is required for 
reliable lymph node staging. 
  
                                                                           
 
 
Complications of axillary lymph node dissection  
  Lymphedema, seroma, frozen shoulder, chronic pain syndrome/ 
neuropathies and thrombophlebitis of the axillary vein. 
The axillary lymphnodes should be staged to aid in determining 
prognosis and therapy. 
Removal of Lymphnode level I and II for assessment while 
reducing morbidity from the procedure can be adopted.  
 Factors identified as predictors of axillary lymph node metastasis 
were tumour size, grade and tumor palpability. 
 Steele et al reported sampling 3 or 4 ALNS provides accurate 
assessment of axilla with false negative rate of 10%   
 
3 methods used are: 
1) Axillary lymph node dissection 
2) Axillary node sampling. 
3) Sentinel lymph node biopsy  
 
 Sentinel node is the first node involved in tumour metastasis. 
Identification of SLN done by injecting sulfur colloid labeled with 
technetium, vital blue dye or both in 92-98% of patients. Biopsy of 
sentinel lymph node and complete dissection of axillary lymph node have 
been reported to have a 97.5 to 100% concordance. 
 
                                                                           
 
 
BREAST RECONSTRUCTION 
It is an integral part of management of breast cancer. 
It may either be done immediately following surgery or after 6 
months. Various techniques available are  
1) Implants or expanders. 
2) Autologous tissue 
(i) pedicled flap 
(ii) free flap. 
3) Combination of both. 
 
SUB PECTORAL IMPLANTS  
 Involves placement of a tissue expander subpectorally and creating 
the breast mound by repeated expansion introducting saline and later 
placement by a permanent implant. Modern breast implants are 
manufactured with an outer shell of polydimethyl siloxane (silicone) and 
contains a filler material such as silicone gel to give its volume. The 
disadvantages of implants are 
 1) Leakage of silicone gel into surrounding tissue and 2) Capsule 
Contracture. 
 
AUTOLOGOUS FLAPS 
  They are more complex, expensive procedures requiring 
comprehensive training and experience. 
                                                                           
 
 
TRAM FLAP(Transverse rectus abdominis myocutaneous)  
TRAM flap is the most commonly performed autogenous 
reconstructive procedure. Although first suggested in 1979 by Robbins, 
Hatrampf and coworkers popularized the TRAM flap in 1983. This flap 
can be harvested as a single or double pedicle flap, utilizing the deep 
superior epigastric blood supply.  
 
COMPLICATIONS 
Partial/complete flap necrosis  
Donor site complications can include  
abdominal wall laxity; diastases,  
abdominal skin necrosis, umbilical malposition, seroma, severe 
pain.  
 
LD Myocutaneous flap 
Latissimus dorsi is a flat, triangular muscle that originates from the 
spines of the lumbar and sacral vertebrae and inserts into the intertubular 
groove of the humerus. Its blood supply comes from the thoracodorsal 
artery and from multiple segmental perforators of the lumbar inter-costal 
arteries.  
This flap is ideally suited for single stage reconstruction for women 
with small breasts and a moderate degree of breast ptosis. If the breast 
                                                                           
 
 
volume requirements exceed the available tissue from this region, a breast 
implant can be used to augment the reconstruction.  
The LD myocutaneous flap not only increases the amount of tissue 
between the breast flaps and the prosthesisbut also provides well-
vascuralised muscle that can reduce the amount of caspsular contracture.  
 
II. RADIOTHERAPY 
 It is now proved that radiation therapy not only improves local 
control of breast cancer but along with surgery and chemotherapy 
improves the probability of survival. 
 A number of studies have examined the value of adding 
postoperative RT to adjuvant chemotherapy and important ones are. 
1) British Columbia trial 
2) Denmark trial. 
 In both trials, RT resulted in large reduction in local recurrence. 
The 7 years survival rate for premenopausal patients was 62% with 
radiotherapy compared to 55% without radiotherapy. 
Two main types of techniques  
a) Whole breast irradiation 
  Done following breast conservation surgery. 
b) Loco regional technique 
                                                                           
 
 
  Breast or chest wall, ipsilateral axilla, supra and infra 
clavicular lymph nodes region, internal mammary chain of nodes are 
irradiated. 
 
POST OPERATIVE RADIOTHERAPY 
Postoperative Radiotherapy refers to the use of irradiation to the 
chest wall and draining lymph node regions as an adjuvant after 
mastectomy.  
Breast conserving treatment included removal of bulk of the tumor  
surgically and to use moderate dose of radiation to eradicate any residual 
cancer.  
Careful observation of treated patient determined that best results 
are achieved by delivering relatively small doses of radiation daily over 
extended period.  
The use of breast irradiation after breast conservation surgery is 
associated with a large reduction in the rate of local recurrence.  
For operable stage II, the post op administration of chemotherapy 
and radiotherapy resulted in better local control and higher survival rate 
than the use of either adjuvant treatment alone 
 
INDICATIONS FOR CHEST WALL IRRADIATION  
1) Positive margin or gross residual disease. 
2) T3 tumour, especially with positive node. 
                                                                           
 
 
3) T4 tumour 
4) Four or more positive axillary lymph nodes. 
5) Close surgical margin (< 2cm) 
6) Following breast conservation  therapy. 
 
INDICATIONS FOR AXILLARY IRRADIATION  
1) 4 or more axillary lymph nodes positive. 
2) Extra nodal disease. 
3) Inadequate axillary sampling. 
4) More that 50% of lymph nodes positive. 
 
PALLIATIVE RADIOTHERAPY 
Radiation therapy is effective in relief or avoidance of symptoms of  
metastasis to many different anatomic sites. The most common problem 
is metastases to bone causing pain or threatening structural integrity. 
Using a schedule of 9 Gy in a single increment to 30 Gy in 10 increments 
reported a total response rate of 82%. For patients suffering pain from 
wide spread metastases, a single hemi body irradiation of 6Gy to upper 
body and 8 to 10 Gy to lower body results in 80% to 100% response in 
terms of reduction in pain. In case of locally advanced carcinoma 
moderate total doses of 45 to 50 Gy in 25 fractions in 5 weeks plus a 
                                                                           
 
 
boost of 10 to 15 Gy to high risk sites used pre and post operatively with 
total mastectomy gives good results and least sequel.  
 
OPTIMAL RADIATION THERAPY TECHNIQUE AND DOSES. 
 Following excision of primary tumour and lymph node dissection, 
radiation is delivered to entire breast for a total of 4500 to 5000 CGY 
over 4.5 to 5.5 weeks 100 – 200 CGY / day followed by supplemental 
boost of 1000 to 1600 CGY. 
 
SIDE EFFECTS 
 - Fatigue, Skin erythema, Dry and moist desquamation, Arm  
  Edema  
 - Shoulder discomfort  
 - Progressive Parasthesia / weakness of arm, hands 
 - Radiation pneumonitis 
 - Radiation induced soft tissue sarcoma, osteosarcoma  
  angiosarcoma. 
 - Bronchogenic carcinoma in ipsilateral lung in smokers. 
 
III. CHEMOTHERAPY  
In 1960s first modern trails of combination chemotherapy were 
initiated for breast cancer management. First adjuvant chemotherapy was 
                                                                           
 
 
administered to women with positive nodes; later in 1980s the use was 
extended to node negative women as well.  
Combination chemotherapy has been more effective than single 
agent therapy, single agents generally achieve partial remission of 10% - 
30%, and combination of three or more agents repeated in cycles could 
achieve 50% - 80% response without additive toxicity. The therapeutic 
intervals in combination therapy that allow normal rapidly dividing stem 
cell to recover can explain the lack of toxicity of these regimen. 
 
Aims of Primary Systemic Therapy (PST) 
1. Reduce the risk of disease recurrence by treating potential areas of 
distant microscopic metastatic disease.  
2. To reduce breast and lymph node tumor burden.  
3. To improve surgical respectability.  
4. Provide early information or surrogate, markers for long term 
outcome.  
 Chemotherapy is given to all premenopausal women with positive 
nodes.  
 Chemotherapy is highly effective in keeping patients disease free 
for a longer period after treatment and increase the survival rates in 
premenopausal patients having stageII carcinoma breast. It is started once 
surgical wound is healed. 
                                                                           
 
 
INDICATIONS 
1) Premenopausal patients with positive nodes. 
2) Patients who test negative for estrogen and progesterone 
receptors 
3) Patients presenting with visceral metastasis 
 
Commonly used Chemotherapeutic agents in breast cancer 
Table 3:-  Chemotherapeutic agents in breast cancer 
Regimen Dose / schedule 
Interval 
days 
Cycles 
CMF (standard) 
Cyclophosphomide  
 
Methotrexate 
5-flurouracil 
100mg / m
2
 /d po for 14 
day 
40mg / m
2
 / d IV days 1 
and 8 
600mg / m
2
 /d IV days 1 
an 8 
28 6 
CMF (IV, node 
negative patients) 
Cyclophosphomide 
methotrexate  
5-flurouracil 
 
 
600mg / m
2
 IV 
40mg / m
2
 IV 
600mg / m
2
 IV 
21 12 
CAF  
Cyclophosphomide  
 
Adriamycin 
5- flurouracil 
 
100mg / m
2
 /d Po for 14 
days 
30mg / m
2
 /d IV 1 and 8 
500mg / m
2
 /d IV 1 and 8 
28 6 
CAF 
Cyclophosphomide  
Doxorubucin 
5- flurouracil 
 
600mg / m
2
 IV day 
60mg / m
2
 IV day 
600mg / m
2
 / d IV day 
21-28 4-6 
                                                                           
 
 
 
SIDE EFFECTS 
 
 Alopecia, Bone Marrow suppression, Immuno suppression, Nausea 
/ vomiting, Cardio toxicity 
 
ADJUVANT HORMONE THERAPY 
It is thought that carcinoma breast is a systemic disease since its  
appearance and by the time tumor has grown to 1 cm size it would have  
metastasised and it is thought that occult  metastasis is already present 
with operable carcinoma. It is observed in clinical trials that improvement 
in long term outlook for newly diagnosed breast cancer even the early 
stage can only be accomplished with systemic therapy. Since the 
introduction of the chemotherapy as adjuvant treatment, it has been 
decreasing the death rate  
 
TAMOXIFEN  
Tamoxifen is the most preferred drug for adjuvant hormone 
therapy and prevention of recurrence over the last two decades. It acts by 
selective modulation of  estrogen receptors thus inhibiting estrogen from 
acting on its receptor. Studies have shown that Tamoxifen reduces relapse 
in patients by as much as 47% after treatment for 5 years and 36% 
decrease in proportional risk of death by 10 years. 
                                                                           
 
 
Tamoxifen is given to post menopausal women with positive 
hormone receptor assay. It is given in the dose of 20mg daily for 5 years. 
SIDE EFFECTS 
 Flushing, Vaginal dryness, Weight gain, Endometrial cancer, 
Thromboembolism 
 
Table 4:- Guidelines for Chemo / Hormonal Therapy 
Node Positive Premenopausal Postmenopausal 
ER / PR + ve 
 
ER / PR – ve 
Combination chemo 
therapy + Tamoxifen  
CCT 
Tamoxifen   ± CCT  
 
CCT ± Tamoxifen 
Node Negative   
Favorable tumour 
character  
unfavorable  
Tamoxifen 
CCT 
Tamoxifen 
Tamoxifen 
Favorable : Size < 2cm. ER / PR + ve, histological grade I,II. 
Unfavorable : Size > 2cm. ER / PR – ve, histological grade III. 
 
  
                                                                           
 
 
AROMATASE INHIBITORS 
 The third generation aromatase inhibitors exemestane, anastrezole , 
letrozole have been proven to show more efficacy than tamoxifen in 
treatment of metastatic carcinoma breast with ER positive status in 
postmenopausal patients. MA17 trial demonstrated reduced risk of 
recurrence of carcinoma breast  and , decreased risk of development of 
contra lateral breast cancer improvement in overall survival in women 
with positive nodes and have received aromatase inhibitors.  
 
Table 5:- Aromatase inhibitors-dosage and adverse effects 
DRUG /  DOSAGE ADVERSE EFFECT 
Anastrozole 1 mg / d Hot flushes, fatigue, vaginal 
dryness nausea, diarrhoea headache, 
osteoporosis, rarely DVT, MI 
Stroke.  
Exemestane 2.5 mg / day Hot flushes, nausea, fatigue 
Sweating, decreased Bone mineral 
density, lymphocytopenia  
Letrozole 2.5 mg / day Hot flushes, arthalagia, myalgia, 
faligue dizziness osteoporosis 
decreased bone mineral density 
rarely M.I, stoke. 
 
 
                                                                           
 
 
TRASTUZUMAB  
 Overexpression of her2 / neu receptors is known to occur in 
roughly 25% of cases of breast cancer. A 3 year study showed that its 
addition to chemotherapy decreased recurrence risk by 50% and 
increased survival rates of patients by 20%.  It belongs to the monoclonal 
antibody group of drugs and acts by binding to her2/neu receptors. 
 
OOPHORECTOMY 
Oophorectomy described by Beaston was the only ablative 
procedure for  years. This bilateral oophorectomy is presumed to work by 
elimination of ovarian hormones including oestrogen, progesterone and 
androgen. This produces objective regression of the disease process. The 
amount of regression was increased with exclusion of ER-velesions. 
Little can be gained with opphorectomy in postmenopausal women, as 
there is nosecretion of hormones from the ovaries of postmenopausal 
women. Surgical castration is preferred because it acts rapidly and results 
in complete reduction in hormone levels. The patients who are unfit or 
refuse surgery can undergo radiation ablation but it takes a minimum of 
two months to completely suppress the hormones by radiation 
  
                                                                           
 
 
ADRENALECTOMY 
Adrenalectomy was popular in earlier days as it showed regression 
of metastatic disease. Because of less risk, less side effects and as it is 
more familiar  to the surgeons operating carcinoma breast, it was very 
commonly used. This was known to increase disease free interval in 
metastatic disease 
 
  
                                                                           
 
 
PROGNOSTIC FACTORS IN BREAST CANCER 
 
A. COMMONLY ASSESSED 
1. Number of involved lymph nodes in axilla 
2. Tumour size 
3. Tumour TNM Stage 
4. Lymph vascular invasion 
5. Histologic Tumour type 
6. Histologic Grade 
7. Nuclear grade 
8. Sex steroid receptor 
9. Ploidy 
10. Proliferative indices (S Phase fraction, Thymidine labeling index, 
mitotic index) 
 
B. INVESTIGATIONAL 
1. Proliferative indices  
 (Ki67, PCNA / Cycline, M1B1) 
2.  His tone H3 
3. Transforming growth factor (a,b). 
4. Epidermal growth factor 
5. Insulin like growth factor 
6. Once gene products (HER2 / neu or cerb B2, C-myc, ras) 
                                                                           
 
 
7. P53 Protein 
8. Invasion related markers 
 (Cathepein D, Stamelysin 3, Laminin receptor)  
9. Angiogenesis factors(PS2, heat stock protein, MDRI) 
 
I. TUMOUR SIZE 
 < 2 cm – favorable 
 > 2 cm – Bad prognosis 
 
II. LYMPH NODE STATUS 
 Positive axillary nodes are the major risk factor for systemic 
disease and most oncologists believe that all women with involved lymph 
nodes should have adjuvant therapy because the clinical staging of 
axillary nodes is so inaccurate.  
Axillary LN dissection is necessary to stage patient accurately and 
to determine the benefit of adjuvant therapy 
No histological involvement  - 80% 5 year Survival  
1-3 positive Lymph nodes - 50% 5 year Survival  
> 4 positive Lymph nodes - 21% 5 year Survival  
III. Tumour Type 
Mucinous Papillary, Tubular, medullary - favourable prognosis   
 
                                                                           
 
 
IV. TUMOUR GRADE 
 Based on Bloom and Richardson grading includes 
- Tendency to form tubules 
- Pleomorphism 
- Hyper chromatic nuclei and mitotic figures  
 Grade I, II - good prognosis  
 Grade III - poor prognosis 
 
Table 6:- Bloom and Richardson histological grading of tumor in 
carcinoma breast 
POINTS 
TUBULAR 
GRADE 
NUCLEAR 
GRADE 
MITOTIC 
INDEX 
1. Well differentiated if 
tubular structures 
constitute greater 
than 75% of tumour 
Small, uniform 
staining nucleus 
Low (.0-3.3 / 
mm
2
) 
2. Tubular structures 
represent 10 –75% 
of tumour 
Moderate 
variation in 
nuclear size and 
shape 
Medium(3.3-
7/mm
2
) 
3. Tubular structures 
represent less than 
10% of tumour 
Marked nuclear 
pleomorphism 
with dark 
staining 
High > 7/mm
2
 
 
Well differentiated cancer - 3-5 Pts  - GRADE I 
Moderately differentiated - 6-7 Pts  - GRADE II 
Poorly differentiated  - 8-9 Pts  - GRADE III 
                                                                           
 
 
V. HORMONAL STATUS 
 ER / PR Positive  - Good prognosis 
VI. HER-2 NEU 
 Over expression of HER-2 neu  is a poor prognostic factor in breast 
carcinoma. 
 
A) RISK FACTOR BIOMARKERS 
 These constitute factors such as familial clustering, hereditary germ 
line mutations,  proliferative breast disease showing atypia, densities in 
mammogram. 
 
B) EXPOSURE BIOMARKERS 
 Include measurement of carcinogen exposure such as DNA 
adducts. 
 
C) DRUG EFFECT BIOMARKERS 
The biochemical effect of drugs can be assessed by serum levels of 
enzymes like glutathione reductase and ornithine decarboxylase. 
 
D) PROGNOSTIC BIOMARKERS 
A)  INDICES OF PROLIFERATION  
PCNA is DNA polymerase associated nuclear protein showing 
increased expression in G1 phase. Its correlates with high S phase 
fraction, aneuploidy, high mitotic index, high tumour grade. 
 
                                                                           
 
 
 
B) INDICES OF ANGIOGENESIS  
Tumor invasion in breast cancer occurs through angiogenesis. Over 
expression of VEGF (Vascular Endothelial Growth Factor)  correlates 
with recurrence of carcinoma breast with lymph nodes testing negative 
for cancer cells. 
a) p53: 
  P53 is a tumor suppressor gene. It plays a key action in DNA 
repair, arresting the cell cycle, and apoptosis . Cells with overexpression 
of p53 show high nuclear grade, high preliferative fraction, aneuploidy, 
hormone receptor negative status. 
A study of molecular biomarkers as prognostic factors in 
carcinoma breast was conducted in the University of Alabama at 
Birmingham. It was found that the combination of Her/2 neu and p53 
overexpression was superior to clinicopathologic factors in predicting 
disease free period and survival rate among patients with carcinoma 
breast. 
  
OVERVIEW OF BREAST CANCER THERAPY 
I. CARCINOMA – IN SITU (STAGE 0) 
1) DCIS involving two or more quadrants require mastectomy. 
2) Limited disease – lumpectomy + radiation therapy 
                                                                           
 
 
3) Low grade DCIS, < 0.5cm – Lumpectomy alone 
4) Nonpalpable DCIS – Needle localization and surgical resection 
 Adjuvant tamoxifen in patients who underwent mastectomy has 
brought the recurrence rates and mortality below 2% 
Patients who underwent lumpectomy and radiotherapy had local 
recurrence rate of 9% mortality 2%. 
Recurrence occurred when tumor size is more than 2.5 cm, DCIS 
was of comedo type. 
LCIS 
Invasive cancer occurs in 25 to 30% of patients presenting with 
LCIS. LCIS is a marker of increased risk of invasive cancer. It is advised 
to observe these patients with or without tamoxifen and to identify as 
early as possible the occurrence of invasive carcinoma through regular 
screening. Excision of LCIS does not confer any benefit because it 
diffusely pervades both breasts with equal risk for invasive disease. 
 
 
Table 7:-  Van Nuys Prognostic index for DCIS 
Score Size 
Margin of 
excision 
Grade 
1. < 1.5 cm > 0.9 cm Non high grade, no necrosis  
2. 1.5 – 4 cm 0.1 – 0.9 cm Non high grade with necrosis 
3. > 4 cm < 0.1 cm High grade with or with out 
necrosis 
 3 – 4 -> small low grade lesions treated by excision alone. 
                                                                           
 
 
5 – 7 -> Excision + Radiation 
8 – 9 -> Mastectomy  
III. EARLY BREAST CANCER 
Includes stage I, II A, II B 
SURGICAL TREATMENT 
1) Breast conserving surgery including 
 Lumpectomy, irradiation of breast tissue , staging of axillary nodes 
2) Modified Radical mastectomy 
 
ADJUVANT RADIATION THERAPY  
 4 or more nodes positive  
 
ADJUVANT CHEMOTHERAPY  
 All nodes positive cancers 
 All node negative cancers with adverse prognostic factors like high 
nuclear histologic grade, negative hormone receptor status. 
 
CONTRAINDICATION TO BREAST CONSERVATION 
SURGERY  
1) Multicentric disease 
2) Prior radiation therapy  
3) Positive surgical margins  
4) Contraindication for radiotherapy 
5) Connective tissue disorder 
                                                                           
 
 
 
III. LOCALLY ADVANCED BREAST CANCER 
(STAGE III A / III B) 
A) Operable disease (Stage III a) 
Modified radical mastectomy, with subsequent adjuvant 
chemotherapy and radiotherapy. 
Chemotherapy - maximize distant disease free survival 
Radiotherapy - maximize loco regional disease free  
    survival  
B) In selected stage III a patients 
Neo adjuvant chemotherapy is used to decrease tumor size and 
facilitate breast conservation surgery  
C) Inoperable stage III A / III B / IIIC   
Neo adjuvant chemotherapy is used to decrease loco regional 
tumor burden  permitting subsequent surgery followed by adjuvant 
chemo and radiotherapy. 
 
IV. METASTASIC DISEASE (STAGE  IV) 
Treatment for stage IV disease is mainly to enhance a woman’s 
quality of life.  
 
                                                                           
 
 
HORMONE THERAPY 
 Given in patients testing positive for hormone recptors, women 
with limited metastastic to visceral tissue who are asymptomatic, and 
presenting metastasis to bone and soft tissues only. 
 
SYSTEMIC CHEMOTHERAPY 
INDICATIONS  
1) Women with ER/PR negative cancer 
2) Symptomatic patients with visceral involvement 
3) Metastasis not responding to hormone therapy 
 
SURGERY  
Mastectomy for fungating breast cancer, Pleural effusion, 
Pericardial effusion, Pathologic fracture, Spinal cord compression    
 
RADIATION THERAPY 
Radiation therapy is effective in alleviating the bone pain from 
tumor progression. Radiation is used as first line for solitary metastasis. 
The effective dose for palliation has not been evolved and various trials 
have shown 8 Gy at 4 weeks as a single fraction schedule is optimal. 
 
FOLLOW UP 
 American society of clinical oncology recommendations for breast 
cancer follow up care. 
                                                                           
 
 
1. All patients should learn correct method of breast self 
examination and should practice it every month. 
2. Follow up for first 2 years: visit at 3 months interval 
 At 3 monthly interval : history, physical examination 
 At 6 monthly interval : blood count and biochemistry, USG abdomen 
mammography  
 At yearly interval : chest X ray, pelvic examination and pap smear, 
mammography  
Follow up for Next 3 years: visit at 6 months interval 
 At 6 monthly interval: history, physical examination 
 At yearly interval : blood count and biochemistry, USG 
abdomen mammography chest X ray,  pelvic examination 
and pap smear.  
Follow up for Next 5 years: visit at 1 year interval 
 At yearly interval : history, physical examination 
 At 2 yearly interval: blood count and biochemistry, USG  
   Abdomen mammography chest X ray, pelvic 
examination  
   and pap smear.  
 
                                                                           
 
 
 
BREAST CANCER PROGNOSIS 
5 years survival rate for  
 Stage I   94%   III A  52% 
 Stage II a  85%  III B  48% 
 Stage II b  70%  IV  18% 
 
TREATMENT 
 Modified radical mastectomy / Radical mastectomy when muscle is 
involved is the treatment of choice with postoperative radiotherapy and 
adjuvant CMF in node positive males. 
 
 
 
 
 
 
 
 
                                                                           
 
 
 
 
 
 
 
METHODOLOGY   
                                                                           
 
 
METHODOLOGY 
 
1) SOURCE OF DATA: 
Cases admitted in KAPV Medical College and Mahatma Gandhi 
Memorial Government Hospital  with carcinoma breast 
 
2) STUDY DESIGN AND SAMPLING: 
This is a prospective analytical study of 95 Cases of Cancer Breast 
diagnosed and treated at KAPV Government Medical College and 
Mahatma Gandhi Memorial Government Hospital, Tiruchirapalli over a 
period of 2 years from May 2012 to August 2014. 
                    
 At presentation a detailed history was taken and clinical 
examination done. Diagnosis was confirmed histologically and 
investigations like Blood Biochemistry, chest X-ray, ultrasound abdomen 
were also done to stage the disease. In patients presenting with locally 
advanced breast disease or metastatic disease investigations like CT 
abdomen, CT chest, mammogram of opposite breast, pleural fluid and 
ascitic fluid cytology were done. 
 
 The modality of treatment was decided based on stage of disease at 
presentation and operability. Most of the patients with early breast cancer 
I,            II A, II B, III A underwent modified radical mastectomy.  
                                                                           
 
 
 
 Inoperable stage IIIA, IIIB, IIIC were treated with neoadjuvant 
chemotherapy followed by modified Radical mastectomy. Metastatic 
disease received palliative chemotherapy and radiotherapy. 
 
 All cases were followed up at monthly interval with clinical 
examination, blood count and biochemistry, ultrasound abdomen, chest X 
ray, Mammography was done at 3 monthly interval during the follow up 
period. Data obtained were recorded in a specific proforma and analysed 
in systematic way. 
 
INCLUSION CRITERIA 
  All histologically proven cases of cancer breast were included in 
the study. Immunohistochemical studies of ER, PR receptors were  done 
in 20 patients 
 
EXCLUSION CRITERIA 
 patients who where operated and referred for further management 
from outside hospital were excluded from the study. 
 
  
                                                                           
 
 
 
 
 
 
OBSERVATION AND 
DISCUSSION 
  
                                                                           
 
 
OBSERVATION AND DISCUSSION 
SEX 
 Only < 1% of cases of cancer breast occurred in men. In our study 
only two patients were male. One had invasive intraductal carcinoma and 
was treated with modified Radical mastectomy and other had malignant 
fibrous histiocytoma with lung metastasis during presentation treated with 
chemotherapy. They account for 2.10%. 
 
AGE 
 Incidence of breast cancer increases with age. In U.S lifetime risk 
of developing breast cancer is 12.2% or 1in 8 women. The incidence of 
carcinoma breast adjusted for age  shows increase in incidence to 4% 
between 1980 and increase occurred primarily in women aged 55 yrs or 
older.  
 
In our study.  
  
                                                                           
 
 
Table 8:- Age wise distribution of breast cancer cases in KAPV 
Age Group 
(years) 
 
No. of Patients 
 
Percentage 
< 30 2 2.10% 
30-40 22 23.14% 
40-50 45 47.36% 
50-60 22 23.14% 
60-70 4 4.21% 
 
Youngest age was 24 years. 
Oldest age was 65 years. 
 
Graph 1: Age wise distribution of breast cancer cases in KAPV 
Most of our patients were between 40 – 50 years. 
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FAMILY HISTORY 
Women with first degree relatives affected by carcinoma breast 
have a 1.7 to 2.5 relative risk of breast cancer development. 1.5 with an 
affected second degree relative. About 5% of breast cancers appear to 
have inherited gene mutations that are dominant and highly penetrant. 
In our study there was no significant family history. 
 
SOCIOECONOMIC STATUS 
Cancer breast is more common in women of higher socioeconomic 
status, but in our study most of the patients belonged to lower 
socioeconomic status.  
This can be explained by the fact that most of the people utilizing 
the health services of this institution are from lower socioeconomic 
group. 
DIETARY FACTORS 
 Epidemiological studies of fat consumption and cancer risk have 
produced inconclusive results. But however weight does correlate with 
breast cancer risk. Multiple studies demonstrate a relative risk of 1.4 for 
each 24 Grams of alcohol (about two drinks) consumed  
 In our study all were taking mixed diet. None of them consumed 
alcohol. 
 
                                                                           
 
 
(IONISING RADIATION) ENVIRONMENTAL FACTORS 
 Radiation exposure after age 40 produces minimal increase in risk.  
Women with Hodgkins disease younger than 15 years of age treated with 
mantle radiation demonstrate a higher risk for carcinoma breast than the 
general population.  High electromagnetic fields and environmental 
exposure to organochlorine pesticides are known risk factors in the 
development of carcinoma breast.  
 In our study none gave history of previous radiation 
MENSTRUAL STATUS 
Increased exposure to endogenous estrogen peaks during menstrual 
cycle and predisposes to carcinoma breast. For every year of delay in 
menarche, there is an apparent decreased risk of breast carcinoma by 
20%. Women with menopause after 55 years have twice the risk of 
developing carcinoma breast compared to women attaining natural 
menopause before 45 years. 
  In our study 3 patients attained menarche before age of 12 and 6 
attained menopause after 55 years 4 underwent total abdominal 
hystrectomy with bilateral salphingo opherectomy for co.existing 
gynaecological problems like dysfunctional uterine bleeding, fibroid 
45 patients were premenopausal 47.36% 
44 Patents were postmenopausal 46.31% 
                                                                           
 
 
 
PARITY 
 Nulliparous women have a relative risk of about 1.4.  
 In our study 5 patients were nullipous which was about 5.26%. 
 
AGE AT FIRST PREGNANCY 
 First full term pregnancy after age 30 have a twofold to fivefold 
increase in breast cancer risk compared with women having a first full 
term pregnancy before age 18 or 19. In our study 9 patients had their 
first child above the age of 28 years. 
 
LACTATION 
It is difficult to determine the beneficials effects of breast feeding 
independent of pregnancy with regards to breast cancer. Some studies 
indicate that breast feeding for longer duration of time has a protective 
effect. 
In our study 3 patients had not breast fed their children. 
 
ORAL CONTRACEPTIVE PILLS  
Women who are on oral contraceptive pills have a 1.24 relative risk 
of developing carcinoma breast. On stopping therapy risk diminishes to 
1.01 over ensuring 10 years. 
                                                                           
 
 
 
HORMONE REPLACEMENT THERAPY  
 Estrogen replacement therapy increases relative risk by 1.8 for use 
of 5 years or less and 2.65 for longer than 5 years.  
In our study none of the patients had used either OCP/HRT. 
  
                                                                           
 
 
 
 
Figure 14: Cancer en cuirasse 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Paget’s disease of the nipple 
                                                                           
 
 
 
Figure 16: Peau d’orange appearance 
 
 
Figure 17: Ulcerative growth 
 
  
                                                                           
 
 
CLINICAL PRESENTATION 
• In our study clinical presentation were as follows 
Table 9:- Clinical presentation of breast cancer in KAPV  
 
 
Graph 2: Clinical presentation of breast cancer in KAPV 
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 NO. OF PATIENTS PERCENTAGE 
Painless lump 52 54 
Lump with pain 24 25.24 
Lump with ulcer 3 3.14 
Nipple discharge 12 12.63 
Metastatic symptoms 4 4.21 
                                                                           
 
 
Most of the patients present with painless lump  
1 – Presented with weakness of lower limb  
1 – Presented with Seizures  
2- dyspnea  
 
SITE OF INVOLVEMENT 
• Commonest site involved in ca breast is upper outer Quadrant. 
In our study it was as follows. 
 
Table 10:- Distribution of site of tumor 
SITE NUMBER PERCENTAGE 
Upper outer 54 56.84% 
Upper inner 12 12.63% 
Lower outer 4 4.21% 
Lower inner 4 4.21% 
Central 12 12.63% 
All 9 9.46% 
 
  
                                                                           
 
 
Table 11:- Tumor size at the time of presentation 
SIZE IN (CMS) NUMBER PERCENTAGE 
<2 1 1.05% 
2-5 25 28% 
>5 64 71% 
 
Graph 3: Tumor size during presentation 
Increased tumor size is associated with early local recurrence, 5 
cases who had local recurrence in our study had tumor size greater than 8 
cm during presentation. 
Four patients with lung metastasis had tumor size  than larger than 
8 cm  
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Table 12:- Lymphnode Involvement in Relation to Survival Rates 
No. of nodes No. of patients % 5 years survival 
Nil 29 31% 80% 
<3. 54 57% 50% 
>3 12 12% 21% 
 
Graph 4: Lymph node involvement in relation to survival rates 
69 patients show clinically positive lymphnodes  
21are node negative 
3 – had bilateral axillary nodes 
More than 3 nodes were positive in 12 of our patients 
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Of which one patient presented with lung metastasis 4 patients developed 
local recurrence during follow up  
3 had opposite axillary node involvement during follow up  
3 had supraclavicular node involvement 
One patient with supraclavicular node involvement developed liver 
metastasis 
 
Table 13:-  Stage at Presentation of Breast Cancer 
STAGE NUMBER PERCENTAGE 
Carcinoma in situ 1 1.05 
II A 9 9.47 
II B 22 23.15 
III A 26 27.36 
III B 33 34.73 
IV 4 4.21 
 
Most of the patients presented in stage III that is 62.09% for which 
5 year survival rate is only about 41%. 
 
 
                                                                           
 
 
 
 
  
Graph 5: Stage at presentation of breast cancer 
2 patients who later developed lung metastasis where of stage III B 
one patient developed liver metastasis. 
3 patients later developed local recurrence 
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TABLE 14:- Incidence of Breast Carcinoma according to 
Histopathological Types 
In our study Pathological varieties encountered were as follows.  
TYPE 
NUMBER OF 
CASES 
PERCENTAGE 
Invasive ductal 
carcinoma  
80 84.21% 
Ductal carcinoma in 
situ 
1 1.05% 
Lobular carcinoma 2 2.10% 
Malignant Phylloides 1 1.05% 
Lobular + Ductal 
component 
2 2.10% 
Fibrous Histiocytoma 1 1.05% 
Colloid carcinoma 1 1.05% 
Medullary carcinoma 3 3.14% 
Pagets  1 1.05% 
Papillary carcinoma 1 1.05% 
Mucinous carcinoma 1 1.05% 
Metaplastic carcinoma 1 1.05% 
 
                                                                           
 
 
Breast cancer patients affected in a single breast, have roughly 1% 
per year risk of developing primary carcinoma in the opposite breast. 
Women aged less than 55 at presentation and  diagnosis and those 
showing lobular architecture on pathological examination, have a higher 
risk of 1.5% 
In our study,  One patient with malignant fibrous histiocytoma 
presented with lung metastasis. 
All the other patients who developed metastasis are of invasive 
ductal carcinoma 
 
HISTOLOGICAL GRADE OF TUMOR 
Depending on factors such as nuclear pleomorphism, formation of 
tubules and mitotic rate, tumor grading by Bloom and Richardson 
classification is as follows. 
Table 15:- Incidence of breast cancer according to histological grade 
GRADE NUMBER PERCENTAGE 
I 42 53 
II 32 35 
III 10 12 
 
                                                                           
 
 
 
Graph 6: Incidence of breast cancer according to histological grade 
 10 patients are of histological grade III of which 3 developed local 
recurrence  
 2 developed lung secondarius during follow up 
 1 developed spinal metastasis 
 
CORRELATIVE STUDY OF HORMONE RECEPTOR STATUS IN 
BREAST CARCINOMAS:      
The study of hormone receptor (ER, PR) status has been 
undertaken in  20 cases  
Immunohisto chemical analysis was done in paraffin embedded 
tissue blocks, by using the Supersensitive Polymer HRP system based on 
53%35%
12%
HISTOLOGICAL GRADE OF TUMOR
I
II
III
                                                                           
 
 
non-biotin polymeric technology that makes use of two major 
components, Super enhancer and poly- HRP reagent.  
         The retrieved antigen was bound to primary antibody and then 
detected by the addition of secondary antibody conjugated with horse 
radish peroxidase polymer and DAB substrate.  
The score was calculated after adequate colour development which can be 
more readily visualized under a light microscope 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                           
 
 
 
Figure 18:  Immunohistochemistry for Estrogen receptors showing 
strong nuclear positivity in tumour cells. x100 
 
Figure 19: Immunohistochemistry for Estrogen receptor showing 
strong nuclear positivity intumour cells. x400 
                                                                           
 
 
 
Figure 20 : Immunohistochemistry for Progestrone receptor showing 
strong nuclear positivity intumour cells. x100 
 
 
Figure 21: Immunohistochemistry for Progestrone receptor showing 
strong nuclear positivity in tumour cells. x400 
                                                                           
 
 
 
Figure 22 :  Immunohistochemistry showing ER and PR positivex100 
 
 
Figure 23:  Immunohistochemistry showing ER and PR positivex400 
 
                                                                           
 
 
 
Figure 24 : Immunohistochemistry showing ER positive, PR 
negative.x100 
 
Figure 25: Immunohistochemistry showing ER positive, PR 
negative.x400 
                                                                           
 
 
 
Figure 26 : Immunohistochemistry showing ER, PR negative. x100 
 
 
Figure 27: Lobular Carcinoma showing ER Positivity With focal PR 
Positivity. x100 
                                                                           
 
 
 
Figure 28: Mucinous carcinoma - ER Positive, PR Negative.x100 
 
 
Figure 29 : Papillary carcinoma showing strong ER and PR 
positivity.x100 
 
                                                                           
 
 
 
The results are shown below.  
TABLE 16:-  ER status in relation to age groups (n=20): 
Age 
group 
Total no of 
cases 
No of ER+ cases No of ER- cases 
20-29 2 0 2 
30-39 2 1 1 
40-49 6 4 2 
50-59 6 5 1 
60-69 3 2 1 
70-79 1 1 0 
Total 20(100%) 13(65%) 7(35%) 
 
 
TABLE 17:- PR status in relation to age groups (n=20): 
Age group Total no of 
cases 
No of PR+ 
cases 
No of PR- cases 
20-29 2 0 2 
30-39 2 0 2 
40-49 6 2 4 
50-59 6 2 4 
60-69 3 1 2 
70-79 1 0 1 
Total 20 5(25%) 15(75%) 
 
  
                                                                           
 
 
The above tables shows the ER/PR status in correlation with 
different age groups. It was observed that in the total 13 ER positive cases 
and total 5 PR positive cases, majority of the cases were observed in the 
age group of 50-59 years and 40-49 years, but the ER positivity was 
higher in age group 50-59 years compared with the age group of 40-49 
years.  
In the age group 50-59 years, 83.33% (5 of 6 cases) were positive 
for ER and2 of 6 cases were positive for PR. The percentage was found to 
be 66.66% (4 of 6) for ER positive cases and 33.33 % (2 of 6) for PR 
positive cases in age group 40-49 years.There were 2 cases in age group 
20 – 29 years, 1 case in 30-39 age group, 1 case in 60 – 69 age group 
respectively were negative for ER. 
 
HORMONE RECEPTOR STUDIES IN CORRELATION WITH 
MENOPAUSE: 
ER, PR hormone receptor study by immunohistochemistry was done for 
10 patients of the premenopausal age group and 10 patients of the 
postmenopausalage group with IDC NOS type and the results are shown 
below: 
  
                                                                           
 
 
TABLE 18:- Hormone receptor study in correlation with menopause: 
ER/PR STATUS Premenopausal 
(n=10) 
Postmenopausal(n=10) 
ER+, PR+ 2(20%) 3(30%) 
ER+, PR- 3(30%) 5(50%) 
ER-, PR- 5(50%) 2(20%) 
 
 From the above table showing the correlation of menopausal status 
with ER and PR status, it is evident that the hormonal positivity was 
greater in postmenopausal(30%) cases than that in premenopausal 
cases(20%). ER positivity was 80% (8 of 10 total postmenopausal cases) 
in postmenopausal period and 50% (5 of total 10 premenopausal cases) in 
premenopausal period. PR positivity was 30 % (3 of 10 total 
postmenopausal cases) in postmenopausal period which was higher than   
20% (2 of total 10 premenopausal cases) in premenopausal patients.   
 
In a total 13 ER positive cases, 61.53% (8 of 13 total positive 
cases) was observed in postmenopausal period and 38.46%(5 of 13 total 
positive cases) was observed in premenopausal period. In a total of 5 PR 
positive cases, 60% (3 of 5 total positive cases) was observed in 
postmenopausal period and 40%(2 of 5 total positive cases) was observed 
in premenopausal period. The overall percentage of the receptor status of 
                                                                           
 
 
the patients showed that estrogen receptor positive and progesterone 
receptor negative tumours (ER+ and PR-) were highest in 
postmenopausal patients in the study group (50%). In the premenopausal 
group of patients, ER- PR - tumours were the highest which constitutes 
50% whereas ER+ PR + tumours constitute only 20%. 
 
ER, PR study in different histological types of breast cancers: 
In correlating the ER, PR status with different histological types of 
breast cancers, one case of Papillary carcinoma was positive for both ER 
and PR. One case of Infiltrating lobular carcinoma was positive for ER 
and focally positive for PR. One case of Mucinous carcinoma was 
positive for ER but negative for PR.  One case each of metaplastic 
carcinoma and medullary carcinoma in the present study is negative for 
ER and PR 
Prognostic value of ER/PR receptor study 
ER/PR Negative seems to have poor prognosis. 
In our study, ER /PR negative found in 7 patients.Among them one 
patient with ER/PR –ve medullary carcinoma developed local recurrence, 
and one patient with ER/PR –ve metaplasic carcinoma developed lung 
metstasis. 
 
 
                                                                           
 
 
NOTTINGHAM PROGNOSTIC INDEX 
T Size (cms) x 0.2    +Lymphnode stage (1 – 3) + Histological grade 
(1-3) 
    1 – No Node 
    2 – up to 3 Node 
    3 - > 3 Node 
 
  NPI Prognosis 
 
15 years survival 
 
<3 Good 80% 
3.1 – 5.4 Moderate 42% 
>5.4 Poor 13% 
 
In our study  
  NPI   No. of Patients 
  <3    8 
  3.1 – 5.4   55 
  > 5.4    32 
 
                                                                           
 
 
During follow up it was detected out of this 32 patients with NPI 
>5.4, 5 had local recurrence, 3 had lung metastasis, 2 spine  metastasis, 1 
brain metastasis, 2 had supraclavicular node involvement.  
 
INVESTIGATION 
 In our study all the patients were subjected to routine investigation 
like urine albumin, sugar, blood urea sugar, Sr. creatinine, x ray chest, 
Fine needle Aspiration cytology, ultra sound abdomen. 
 Mammogram of opposite breast was done in all locally advanced 
breast cancers. 33 patients underwent mammogram and were found to be 
normal. 
 CT chest, pleural aspiration cytology was done for 2 patients who 
presented with lung secondaries USG abdomen, x ray of long bones and 
vertebrae taken to exclude other metastasis. 
 CT. dorsolumbar spine was done in one  patient who had collapse 
of D6 vertebra for which local radiotherapy was given. 
 CT brain was done in one patient who presented with headache, 
Seizures which showed metastatic deposites in cerebellar hemisphere. 
She developed raised intracranial tension for which ventriculoperitioneal 
shunt was done. 
                                                                           
 
 
CT abdomen was done in patients with Ascites who had multiple 
liver secondaries. Paracentesis was done and malignant deposists detected 
in cytological analysis.  
 
 
MANAGEMENT 
After confirming the diagnosis staging was done by TNM 
classification most of the cases with stage I,IIA,IIB,IIIA were subjected 
to modified radical mastectomy. Inoperable stage IIIA and IIIB, IIIC 
treated with neo adjuvant chemotherapy followed by Madified radical 
mastectomy. Patients with ulcer/ fungating lesion treated with toilet 
mastectomy followed palliative chemo / radio therapy. Adjuvant 
chemotherapy and hormone therapy was given to most of the patients. 
Patients with Brain and spinal metastasis received loco regional radiation.  
  
                                                                           
 
 
Table 19:- Surgical procedures performed on  breast cancer patients 
at KAPV 
TYPE OF SURGERY 
NO : OF 
PATIENTS 
PERCENTAGE 
Modified radical mastectomy 90 94.7 
Toilet mastectomy 5 5.3 
 
 
Graph 7: Surgical management of breast cancer cases in KAPV  
Neoadjuvant chemotherapy with CMF given to 33 patients (all stage III B 
and inoperable stage IIIA stage). 
94.70%
5.30%
MRM
Toilet mastectomy
                                                                           
 
 
 
LYMPHNODE WITH METASTATIC DEPOSITS IN RESECTED 
SPECIMEN 
 
Graph 8: Percentage distribution of  number of lymph nodes showing 
metastatic deposits 
In our study minimum of three to maximum of Twentytwo lymphnodes 
were found in resected specimen among which. 
• No metastatic deposits were found in 20 patients (31 %) 
• 2 nodes positive for deposits in 17 patients. (27%) 
• 2-6 nodes were positive for deposits in 19 patients. (29%) 
• More than 6 nodes were positive for deposits in 13 patients. (13%)  
 
31%
27%
29%
13%
NO NODES
2 NODES
2-6 NODES
>6
                                                                           
 
 
 
RESECTED MARGINS 
• In our study 
• Positive resection margins were found in 5 patients they were given 
radiotherapy 3 of them developed local recurrence. 2 developed 
metastasis one in lung, one in brain.  
 
ADJUVANT THERAPY: 
 Neo adjunt chemotherapy with CMF given to all stage III B 
Patients – 33 
Patients with more than 3 nodes received Chemotherapy- 12 patients 
Patients presenting with metastatic disease received chemotherapy – 4 
patients 
Tamoxifen given to all postmenopausal patients-47 
 
RADIOTHERAPY 
• Adjuvant radiotherapy was given to patients whose Tumor size is more 
than 5 cm or with four or more clinically positive axillary lymphnodes 
or who have positive resection margins after surgery. 
• Tumor size more than 5cm  -  64 patients 
• Positive resection margins found in 17 patients 
 
                                                                           
 
 
FOLLOW UP 
 All the patients were followed up with clinical examination at 
monthly interval and with blood count and biochemistry, ultrasound 
abdomen, Mammography at 3 monthly interval. 
 Follow up period were from 6 months to 20 months. 
 76 out of 95 patients came for regular follow up (80%)  
 In our study, 7 were detected to have local recurrence. They were 
treated with Radiotherapy and chemotherapy. 
 
8 developed   distant metastais  
Lung secondaries  - 4 
Brain secondaries - 1 
Spine metastasis   - 2 
Liver metastasis    -1 
 
They were given chemotherapy . 
CT chest, pleural aspiration cytology for confirmation of malignant 
deposits done in patients  with lung secondaries and pleural effusion  
 
CT Dorsolumbar spine done in patients with spine metastasis one 
had D6 vertebra compression and local radiation was given  
  
                                                                           
 
 
 
CT brain was done in the patients with brain metastasis and one 
developed raisied intracranial pressure for which ventriculoperitoneal 
shunt was done. 
CT abdomen was done in patient with liver metastasis, who had 
Ascites. Paracentesis of Ascitic fluid was done and malignant cells were 
detected in cytological analysis. 
  
                                                                           
 
 
 
 
 
 
 
SUMMARY 
  
                                                                           
 
 
SUMMARY 
In our study the following observations were made.  
1. The commonest age of presentation was 40 – 50 years of age. 
2. About 47.36 were premenopausal and 46.31 were postmenopausal 
5.26% were Nullipara. 
3. Commonest mode of presentation was painless lump in 46.31%. 
4. Most of the patients presented with stage III  disease 62.09%. 
5. Lymphnode positivity during presentation was about 69.46%. 
6. Invasive ductal carcinoma was the commonest pathological variety 
in our stage. Histological grade I was found in 56.84% 
7. Most of our patients presented with Tumor size more than 5 cm 
(67.36%).  
8.  Modified Radical mastectomy was done in 90 patients. Toilet 
mastectomy  was done in 5 patients presenting with 
ulceration/fungating lesions  
9. Resected margins were found to be positive in 5 patients all of 
them were given radiotherapy. Three of them developed 
locoregional recurrence 2 developed metastasis. One in lung, one 
in brain.  
10. Lymphnode examination for metastatic deposits in pathological 
specimen showed positivity in 49 patients. More than 6 nodes were 
positive for metastatic deposits in 13 patients. Of which 4 
                                                                           
 
 
developed locoregional recurrence and one developed liver, lung 
metastasis.  One patient with supraclavicular node developed spine 
metastasis. All patients were treated with chemotherapy and 
radiotherapy.  
11. Histologic grade 1 found in 44.21 of patients, grade 3 found in 
10.52% of our patients (10 Pts) of which 3 had locoregional 
recurrence.  2 developed lung secondaries during the follow up 
period.  
12. Patients who developed lung metastasis had Tumor size more than 
8cm during presentation and 1 of them had histological grade III 
invasive ductal carcinoma. Supraclavicular node was involved in 
one patient.  
13. One patient with brain metastasis had Tumor size of 6 cm during 
presentation, she had more than 6 nodes positive for deposits in 
pathological resection specimen.   
14. .One patient who developed both spine and liver metastasis 
presented with tumor involving all quadrants.  
15. In the hormone receptor study done in 20  cases .(10 cases in 
premenopausal age group and 10 cases in postmenopausal age 
group), estrogenreceptor positivity was seen in 65%  (13cases), 
negativity for both receptors in 35% (7 cases ) with increase in 
positivity in older age group(50-59 years).  
                                                                           
 
 
 1. ER+, PR- tumours (5/10 cases) are more prevalent in 
postmenopausal age group constituting 50%. 
 2. Special histological variants like papillary carcinoma, lobular 
carcinoma are positive for ER and PR.Medullary and Metaplastic 
variants are negative for both receptors. In our study, ER /PR 
negative found in 7 patients.  Among them  one patient with ER/PR 
–ve medullary carcinoma developed local recurrence, and one 
patient with ER/PR –ve metaplasic carcinoma developed lung 
metstasis. 
16. Nottingham Prognostic index was found to have direct correlation 
with prognosis in our study. In 32 of our patients with NPI more 
than 5.4, 5 had local  recurrence, 3 had lung metastasis, 2 
developed spine metastasis and one developed brain metastasis 
during follow up.     
 
 
 
 
 
  
                                                                           
 
 
 
 
 
CONCLUSION 
  
                                                                           
 
 
CONCLUSION 
 The aim of the study is to identify the prognostic factors in primary 
breast cancer. The utility of prognostic factors lies not only in their ability 
to prognosticate the outcome of the disease but also in detecting early 
disease, monitoring of disease course, screening for recurrent disease. 
They also help in deciding upon application of adjuvant systemic therapy 
and in identifying patients of poor prognosis who warrant more 
aggressive investigational therapies. 
 
 Commonly assessed prognostic factors are number of lymphnodes 
in axilla, tumour size, TNM stage, histologic tumour type, histologic 
tumor grade.. Immunohistochemical study of  ER/PR hormone receptor 
in breast cancer patients will lead on to a precise and individualised 
management which will have better impact on the disease free survival 
and overall survival. 
 
        Tumor size has linear relationship with prognosis and eventual 
metastasis. As tumor size increased, survival decreased regardless of 
lymph node status and as lymph node involvement increased, survival 
status decreased regardless of tumor size. Medial lesions have slightly 
worse prognosis than lateral lesions due to involvement of mammary 
nodes. Histological grade of tumor also seems to correlate with 
                                                                           
 
 
regional recurrence and metastasis. Patients with post operative positive 
resection margins were also at high risk of locoregioal recurrence. 
 Hence it is suggested that for patients with breast cancer, the 
prognostic markers that can be routinely assessed are axillary lymphnode 
status, tumour size,histologic grade, estrogen and progesterone receptor 
status, post operative findings like positive margins. They are helpful in 
planning adjuvant treatment. 
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ANNEXURES 
 
  
                                                                           
 
 
PROFORMA 
Name     :  
Age                                                  
IP no     : 
DOA     : 
Address    : 
 
HISTORY    : 
Lump     : 
Duration    : 
Pain     : 
Discharge    : 
Ulcer     : 
Others    : 
Axillary node   : 
Metastasis    : 
 
REPRODUCTIVE HISTORY: 
Age at menarche   : 
Age at child birth   : 
Parity     : 
 
                                                                           
 
 
Duration of breast feeding : 
Menstrual status   : 
Hormonal therapy   : 
 
FAMILY HISTORY  : 
Number of relative affected : 
Other coexisting malignancy : 
Age at cancer detected  : 
Laterality    : 
 
TREATMENT HISTORY : 
Previous benign diseases  : 
Previous malignant disaeases : 
 
PHYSICAL EXAMINATON : 
BREAST MASS   : 
Size     : 
Location    : 
Consistency    : 
Fixity     : 
 
 
                                                                           
 
 
SKIN CHANGES  : 
Erythema    :                                                                                    
Dimpling    : 
Edema/ Peau d’orange 
Satellite nodule   : 
 
NIPPLE CHANGES  : 
Retraction    : 
Eversion    : 
Discoloration   :                                                                              
Discharge    : 
 
AXILLARY NODE  : 
Number    : 
Fixity     : 
Location    : 
Supraclavicular  node  : 
Opposite breast &axilla  : 
Abdomen    : 
Respiratory system  : 
Spine & Cranium   : 
P/R&P/V    : 
Stage     : 
                                                                           
 
 
Investigations   : 
1.FNAC    : 
2.X-Ray Chest   : 
3.Mammogram   : 
4.USG Abdomen   : 
5.CT Thorax   : 
6.LFT    : 
7.Others     :        X-Ray long bones 
                            Bone scan 
SURGERY    : 
HPE REPORT   : 
Type of malignancy  : 
Grade     : 
Resected margin   : 
Lymph node status   : 
Receptor status   :  
ER Status if done   : Positive or Negative 
PR Status if done   : Positive or Negative: 
CHEMOTHERAPY  : 
RADIOTHERAPY  : 
FOLLOW UP   : 
 
                                                                           
 
 
 
Ra xg;Gjy; gbtk; 
khh;gf Gw;WNehapd; jd;ikia jPh;khdpf;Fk; fhjfkhd msTNfhs;fs; gw;wp 
Muha;jy; 
Muha;r;rp epiyak;   : kfhj;kh fhe;jp epidT muR 
kUj;Jtkid, jpUr;rp. 
gq;F ngWk; Nehahspapd; ngah; :      taJ: 
      ghypdk; : Mz;     ngz; 
gq;F ngWk; Nehahspapd; vz; :  
Nehahspapd; ngah; / tpyhrk; : 
Nehahsp ,jid ( ) Fwpf;fTk; : 
 
 NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fs; vdf;F tpsf;fg;gl;lJ 
vd;Dila re;Njfq;fis Nfl;fTk; mjw;fhd jFe;j tpsf;fq;fisg; ngwTk; 
tha;g;gspf;fg;gl;lJ. 
 ehd; ,t;tha;tpy; jd;dpr;irahfj;jhd; gq;Nw;fpNwd;. ve;j 
fhuzj;jpdhNyh ve;j fl;lj;jpYk; ve;j rl;l rpf;fYf;Fk; cl;glhky; vd;id 
,t;tha;tpy; ,Ue;J tpyf;fpf; nfhs;syhk; vd;Wk; mwpe;J nfhz;Nld;. 
 ,e;j Ma;T rk;ge;jkhfNth ,ij rhh;e;j NkYk; Ma;T Nkw;nfhs;Sk; 
NghJk; ,e;j Ma;tpy; gq;FngWk; kUj;Jth; vd;Dila kUj;Jt 
mwpf;iffisg; ghh;g;gjw;F vd; mDkjp Njitapy;iy vd mwpe;J 
nfhs;fpNwd;. ehd; tpyf;fpf; nfhz;lhYk; ,J nghUe;Jk; vd mwpfpNwd;. 
 ,e;j Ma;tpd; %yk; fpilf;Fk; jfty;fisAk; ghpNrhjid 
KbTfisAk; kw;Wk; rpfpr;ir njhlh;ghd jfty;fisAk; kUj;Jth; 
Nkw;nfhs;Sk; Ma;tpy; gad;gLj;jpf;nfhs;sTk; mij ghpNrhjpf;f vd; KO 
kdJld; rk;kjpf;fpNwd;. 
 ,e;j Ma;tpy; vd;id <LgLj;j KOkdJld; xg;Gf; nfhs;fpNwd;. ,e;j 
mWit rpfpr;ir kw;Wk; mjdhy; Vw;glf;$ba gpd; tpisTfs; kw;Wk; 
vjph;ghuhj tpisTfs; gw;wp vdf;F tpsf;fkhfj; njhptpf;fg;gl;lJ. 
 vd; eyd; fUjpNa ,e;j Ma;T Nkw;nfhs;sg;gl;lJ vd;W njhpe;J ,e;j 
Ma;tpw;F xg;gspf;fpd;Nwd;. 
 
Nehahspapd; ifnahg;gk; ……………………….,lk; …………… 
Njjp……………..  
 
fl;il tpuy;Nuif(,e;j gbtk; gbj;J fhl;lg;gl;L Ghpe;J ifNuif 
mspf;fpd;Nwd;) 
Ma;thshpd; ifnahg;gk; ………………….…… ,lk; ………….. 
Njjp………………… 
Ma;thshpd; ngah; ………………………………….   
  
                                                                           
 
 
 
 
  
                                                                           
 
 
 
  
                                                                           
 
 
  
                                                                           
 
 
  
                                                                           
 
 
 
MASTER CHART 
                                                                           
 
 
 
                                                                           
 
 
                                                                           
 
 
 
KEY TO MASTER CHART 
 
Pre   - Pre Menstrual 
Hys  - Hysterectomy 
U.O    - Upper Outer 
MRM  - Modified Radical Mastectomy 
LR   -  Local Recurrence 
IDC   - Intra carcinoma 
IDC/NOS  - Intra Ductal Carcinoma – Not Otherwise Specified 
S.C Node  - Supraclavicular noe 
NPI  - Nottingham Prognostic Index 
 
 
 
